

MOLECULAR IMAGING ADVANCES

CUTTING-EDGE DEVELOPMENTS IN NUCLEAR MEDICINE

Editors:

Maajid Mohi Ud Din Malik

Mansour M. Alqahtani

Bentham Books

Molecular Imaging Advances: Cutting-edge Developments in Nuclear Medicine

Edited by

Maajid Mohi Ud Din Malik

*Dr. D.Y. Patil School of Allied Health Sciences
Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University)
Sant Tukaram Nagar, Pune, Maharashtra, India*

&

Mansour M. Alqahtani

*Department of Radiological Sciences
College of Applied Medical Sciences
Najran University, Najran, Saudi Arabia*

Molecular Imaging Advances: Cutting-edge Developments in Nuclear Medicine

Editors: Maajid Mohi Ud Din Malik & Mansour M. Alqahtani

ISBN (Online): 979-8-89881-354-3

ISBN (Print): 979-8-89881-355-0

ISBN (Paperback): 979-8-89881-356-7

© 2025, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore, in collaboration with Eureka Conferences, USA. All Rights Reserved.

First published in 2025.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

No. 9 Raffles Place

Office No. 26-01

Singapore 048619

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	iii
LIST OF CONTRIBUTORS	iv
CHAPTER 1 NUCLEAR MEDICINE: ESSENTIAL CONCEPTS AND APPLICATIONS	1
<i>Maajid Mohi Ud Din Malik and Mansour M. Alqahtani</i>	
HISTORICAL PERSPECTIVE	2
The Birth of Nuclear Medicine	2
Post-World War II Developments	3
The Rise of Molecular Imaging	3
CURRENT STATE OF THE FIELD	4
Advanced Imaging Technologies	4
<i>Hybrid Imaging Systems</i>	4
<i>Advances in PET Technology</i>	5
<i>SPECT Innovations</i>	5
<i>Image Reconstruction and Processing</i>	6
<i>Multiparametric Imaging</i>	6
Radiopharmaceuticals and Theranostics	7
<i>Advanced Radiopharmaceuticals</i>	7
<i>The Rise of Theranostics</i>	8
CLINICAL VALIDATION AND LONG-TERM OUTCOME CHALLENGES	9
Artificial Intelligence and Big Data	9
<i>Artificial Intelligence in Nuclear Medicine</i>	9
<i>Big Data in Nuclear Medicine</i>	10
<i>Challenges and Future Directions</i>	11
COMPUTATIONAL AND INFRASTRUCTURE CHALLENGES	12
ALGORITHM INTERPRETABILITY AND CLINICAL ACCEPTANCE	12
Radiation Safety and Dose Optimisation	12
<i>Technological Advancements for Dose Reduction</i>	13
<i>Personalised Dosimetry</i>	13
<i>Regulatory Framework and Guidelines</i>	14
<i>Staff and Public Safety</i>	14
<i>Education and Training</i>	14
<i>Future Directions</i>	15
ADDRESSING IMPLEMENTATION BARRIERS	15
Overview of Recent Breakthroughs	16
<i>Next-Generation PET Systems</i>	16
<i>Total-Body PET</i>	16
<i>Digital PET Detectors</i>	17
<i>Advanced Reconstruction Algorithms</i>	17
<i>Multimodal Imaging</i>	18
<i>Implications and Future Directions</i>	18
Advancements in Neuroimaging	18
<i>Tau PET Imaging</i>	19
<i>Synaptic Density Imaging</i>	19
<i>Other Notable Advancements</i>	20
<i>Implications and Future Directions</i>	21
Theranostics and Precision Oncology	21
<i>Principles of Theranostics</i>	21

<i>Prostate Cancer Theranostics</i>	22
<i>Neuroendocrine Tumour Theranostics</i>	23
<i>Emerging Theranostic Applications</i>	23
<i>Precision Oncology and Theranostics</i>	24
<i>Challenges and Future Directions</i>	24
Artificial Intelligence in Image Analysis	25
Novel Radiopharmaceuticals	25
<i>Fibroblast Activation Protein Inhibitors (FAPIs)</i>	26
CLINICAL TRANSLATION CHALLENGES	27
Prostate-Specific Membrane Antigen (PSMA) Ligands	27
Other Emerging Radiopharmaceuticals	29
Challenges and Future Directions	29
Advances in Radionuclide Therapy	30
<i>Principles of Radionuclide Therapy</i>	30
<i>Beta-Emitting Radionuclides</i>	31
<i>Alpha-Emitting Radionuclides</i>	32
<i>Advances in Dosimetry and Treatment Planning</i>	33
<i>Expanding Applications</i>	34
<i>Future Directions</i>	34
Quantitative SPECT	34
<i>Principles of Quantitative SPECT</i>	35
<i>Technological Advancements</i>	35
<i>Clinical Applications</i>	36
QUANTITATIVE ACCURACY LIMITATIONS	37
Challenges and Future Directions	37
CONCLUSION	38
Implementation and Validation Challenges	38
Regulatory and Economic Considerations	39
Future Research Priorities	39
REFERENCES	40
CHAPTER 2 NEXT-GENERATION PET IMAGING TECHNOLOGIES	42
<i>Mansour M. Alqahtani and Maajid Mohi Ud Din Malik</i>	
INTRODUCTION	43
ADVANCEMENTS IN PET SCANNER DESIGN	43
Evolution of Detector Technology	43
<i>Scintillation Crystals</i>	44
<i>Photosensors</i>	44
<i>Improvements in Spatial Resolution</i>	44
<i>Smaller Crystal Elements</i>	45
<i>Depth-of-Interaction (DOI) Detection</i>	45
<i>Advanced Reconstruction Algorithms</i>	45
Enhanced Sensitivity	46
<i>Increased Axial Field of View</i>	46
<i>Improved Detector Efficiency</i>	46
<i>Extended Axial Acceptance Angle</i>	46
Digital PET Systems	46
<i>Key Features of Digital PET</i>	46
<i>Benefits of Digital PET</i>	47
Novel Geometries and Configurations	47
<i>Dedicated Organ-Specific Scanners</i>	47

<i>Insert-Based Systems</i>	47
<i>Adaptive Geometries</i>	48
TIME-OF-FLIGHT PET	48
Principles of Time-of-Flight PET	48
<i>Basic Concept</i>	49
<i>Timing Resolution</i>	49
Technological Enablers of TOF-PET	49
<i>Fast Scintillators</i>	49
<i>Silicon Photomultipliers (SiPMs)</i>	49
<i>High-Speed Electronics</i>	50
Clinical Benefits of TOF-PET	50
<i>Improved Signal-to-Noise Ratio</i>	50
<i>Faster Convergence in Iterative Reconstruction</i>	50
<i>Improved Lesion Detectability</i>	50
<i>Potential for Dose Reduction or Shorter Scan Times</i>	51
Challenges and Limitations	51
<i>System Complexity and Cost</i>	51
<i>Calibration and Quality Control</i>	51
<i>Impact of Patient Size</i>	52
<i>Limited Benefit for Small Objects</i>	52
Future Directions in TOF-PET	52
<i>Quality Control and Calibration Complexities</i>	52
<i>Improved Timing Resolution</i>	53
<i>Integration with Other Advanced Technologies</i>	53
<i>Novel Scintillators and Readout Techniques</i>	53
<i>Clinical Validation and Optimisation</i>	53
TOTAL-BODY PET IMAGING	53
Concept and Development of Total-Body PET	54
<i>Basic Concept</i>	54
<i>Historical Development</i>	54
Technical Challenges and Solutions	54
<i>Detector Cost and Complexity</i>	54
<i>Data Handling and Processing</i>	55
<i>Image Reconstruction</i>	55
<i>Scatter Correction</i>	55
Clinical Applications and Potential Benefits	55
<i>Improved Sensitivity</i>	55
<i>Dynamic Whole-Body Imaging</i>	56
<i>Late-Time-Point Imaging</i>	56
<i>Specific Clinical Applications</i>	56
Research Opportunities with Total-Body PET	56
<i>Multi-Tracer Studies</i>	56
<i>Radiomics and Artificial Intelligence</i>	57
<i>Biodistribution and Dosimetry Studies</i>	57
<i>Systems Biology Approach</i>	57
Economic Considerations and Future Outlook	57
<i>High Initial Cost</i>	57
<i>Operational Costs</i>	57
<i>Reimbursement Challenges</i>	57
<i>Market Segmentation</i>	58
Clinical Evidence Gaps and Required Studies	58

INTEGRATION OF ARTIFICIAL INTELLIGENCE IN PET IMAGING	59
AI in Image Reconstruction	59
AI for Image Analysis and Interpretation	59
AI in Quality Control and Protocol Optimisation	60
Data Privacy and Security Challenges in AI-Enabled PET	60
Regulatory Framework and Algorithm Validation	61
MULTIMODAL IMAGING: PET/CT, PET/MRI, AND BEYOND	61
PET/CT	61
PET/MRI	62
Future Directions in Multimodal Imaging	62
EMERGING TRENDS AND FUTURE PERSPECTIVES	62
Theranostics	63
Personalised Imaging Protocols	63
Novel Radiotracers	63
Integration with Other 'Omics' Data	63
Portable and Point-of-Care PET Systems	63
Quantum Technologies	63
IMPLEMENTATION CHALLENGES AND GLOBAL ACCESSIBILITY	63
COST STRATIFICATION AND ALTERNATIVE MODELS	64
PHASED IMPLEMENTATION STRATEGIES	64
WORKFORCE DEVELOPMENT CHALLENGES	64
Impact on Healthcare Workforce and Professional Roles	64
NUCLEAR MEDICINE TECHNOLOGISTS	65
RADIOLOGISTS AND NUCLEAR MEDICINE PHYSICIANS	65
MEDICAL PHYSICISTS	65
TRAINING AND CERTIFICATION REQUIREMENTS	66
Expanded Conclusion and Recommendations	66
IMPLEMENTATION READINESS ASSESSMENT	66
RECOMMENDATIONS BY HEALTHCARE SETTING	66
FUTURE RESEARCH PRIORITIES	67
ADDRESSING IMPLEMENTATION BARRIERS	67
LONG-TERM PERSPECTIVE	67
LIMITATIONS AND FUTURE RESEARCH NEEDS	67
CONCLUSION	68
REFERENCES	69
CHAPTER 3 SPECT/CT AND PET/CT: HYBRID IMAGING INNOVATIONS	71
<i>Maajid Mohi Ud Din Malik and Mansour M. Alqahtani</i>	
INTRODUCTION	71
TECHNOLOGICAL IMPROVEMENTS IN HYBRID SYSTEMS	73
SPECT/CT Advancements	73
PET/CT Innovations	75
CLINICAL APPLICATIONS AND BENEFITS	76
Oncology	76
Cardiology	78
Neurology	78
Other Clinical Applications	79
FUTURE DIRECTIONS IN MULTIMODALITY IMAGING	80
PET/MRI	80
<i>Technical Challenges and Solutions</i>	81
<i>Clinical Applications</i>	81

<i>Research Applications</i>	82
<i>Challenges and Future Directions</i>	83
SPECT/MRI	84
<i>Technical Developments</i>	84
<i>Potential Applications</i>	85
<i>Challenges and Future Directions</i>	86
Total-Body PET	86
<i>Technical Innovations</i>	86
<i>Potential Benefits</i>	87
<i>Clinical and Research Applications</i>	88
<i>Challenges and Future Directions</i>	88
Novel Radiotracers and Theranostics	90
<i>Novel PET Tracers</i>	90
<i>SPECT Tracer Innovations</i>	91
<i>Theranostics</i>	92
<i>Challenges and Future Directions</i>	93
STANDARDISATION AND QUALITY ASSURANCE REQUIREMENTS	94
Artificial Intelligence in Hybrid Imaging	95
<i>Image Reconstruction</i>	95
<i>Image Analysis and Interpretation</i>	96
<i>Clinical Decision Support</i>	97
<i>Challenges and Future Directions (AI in Hybrid Imaging)</i>	97
CONCLUSION	100
Technological Advancements	100
Clinical Impact	101
Quantification and Standardisation	102
Emerging Technologies and Future Directions	102
Challenges and Opportunities	103
Interdisciplinary Collaboration and Translational Research	104
Personalised Medicine and Precision Health	104
REFERENCES	105
CHAPTER 4 THE AI REVOLUTION IN NUCLEAR MEDICINE	108
<i>Mansour M. Alqahtani and Maajid Mohi Ud Din Malik</i>	
INTRODUCTION	109
AI-ASSISTED IMAGE RECONSTRUCTION AND ANALYSIS	110
Fundamentals of Nuclear Medicine Imaging	110
Traditional Image Reconstruction Methods	110
AI-Driven Image Reconstruction Techniques	110
AI in Image Analysis and Interpretation	112
MACHINE LEARNING FOR IMPROVED DIAGNOSTICS	113
Overview of Machine Learning in Medical Imaging	113
Supervised Learning Approaches in Nuclear Medicine	113
Unsupervised Learning and Anomaly Detection	114
Deep Learning Applications in Nuclear Medicine Diagnostics	115
PREDICTIVE MODELLING IN TREATMENT PLANNING	117
AI-Driven Personalised Treatment Planning	117
Radiomics and Treatment Response Prediction	117
AI in Dosimetry and Radiation Therapy Optimisation	119
CHALLENGES AND FUTURE DIRECTIONS	121
Clinical Implementation Challenges and Failure Analysis	121

Data Quality and Standardisation	122
Model Interpretability and Explainability	122
Clinical Validation and Regulatory Approval	123
Integration into Clinical Workflows	123
Ethical Considerations and Patient Trust	123
EMERGING TECHNOLOGIES AND FUTURE APPLICATIONS	124
CONCLUSION	126
REFERENCES	127
CHAPTER 5 THERANOSTICS: PERSONALIZED RADIOPHARMACEUTICAL THERAPY	129
<i>Ajai Kumar Shukla, Maajid Mohi Ud Din Malik and Mansour M. Alqahtani</i>	
INTRODUCTION	129
PRINCIPLES OF THERANOSTICS	132
Molecular Targeting	132
Theranostic Pairs	133
The Theranostic Workflow	133
Radiobiology of Targeted Radionuclide Therapy	134
RECENT DEVELOPMENTS IN TARGETED RADIONUCLIDE THERAPY	135
RADIOBIOLOGICAL MECHANISMS AND COMPARATIVE EFFICACY	135
Novel Radiopharmaceuticals	136
<i>PSMA-Targeted Agents</i>	136
<i>Fibroblast Activation Protein Inhibitors (FAPIs)</i>	136
<i>Alpha-Emitting Radiopharmaceuticals</i>	137
Advances in Radiochemistry	137
Combination Therapies	137
Personalised Dosimetry	137
CASE STUDIES	138
Neuroendocrine Tumours	138
<i>Diagnostic Imaging</i>	138
<i>Peptide Receptor Radionuclide Therapy (PRRT)</i>	139
<i>Patient Selection and Treatment Planning</i>	139
<i>Treatment Response and Follow-up</i>	139
<i>Challenges and Future Directions</i>	140
Prostate Cancer	141
<i>Diagnostic Imaging</i>	141
<i>PSMA-Targeted Radionuclide Therapy</i>	142
<i>Patient Selection and Treatment Planning</i>	142
<i>Treatment Response and Follow-up</i>	142
<i>Challenges and Future Directions</i>	143
CHALLENGES AND FUTURE PERSPECTIVES	144
CONCLUSION	146
DECLARATION	147
REFERENCES	147
CHAPTER 6 NOVEL RADIOPHARMACEUTICALS AND RADIOTRACERS	149
<i>Rajesh A. Kinhikar and Maajid Mohi Ud Din Malik</i>	
INTRODUCTION	149
EMERGING RADIOTRACERS FOR NEUROIMAGING	151
Radiotracers for Neurodegenerative Diseases	151
<i>Amyloid Imaging</i>	151
<i>Tau Imaging</i>	152
<i>Synapse Density Imaging</i>	153

Radiotracers for Psychiatric Disorders	154
<i>Serotonin System Imaging</i>	154
<i>Glutamate System Imaging</i>	154
Neuroinflammation Imaging	154
<i>TSPO Imaging</i>	155
<i>Novel Targets for Neuroinflammation Imaging</i>	155
INNOVATIONS IN ONCOLOGICAL IMAGING AGENTS	155
Novel Metabolic Tracers	156
<i>Amino Acid Tracers</i>	156
<i>Lipid Synthesis Tracers</i>	156
<i>Prostate-Specific Membrane Antigen (PSMA) Tracers</i>	157
<i>Somatostatin Receptor Imaging</i>	157
<i>Fibroblast Activation Protein (FAP) Inhibitors</i>	157
Hypoxia Imaging	159
Proliferation Imaging	159
Immuno-PET	160
ADVANCEMENTS IN CARDIOVASCULAR NUCLEAR MEDICINE	161
Novel Myocardial Perfusion Imaging Agents	161
<i>18F-Flurpiridaz</i>	161
<i>82Rb and 13N-Ammonia</i>	161
Cardiac Innervation Imaging	161
<i>123I-MIBG</i>	162
<i>11C-Hydroxyephedrine</i>	162
Atherosclerosis Imaging	162
<i>18F-NaF for Microcalcification</i>	162
<i>68Ga-DOTATATE for Inflammation</i>	163
<i>VCAM-1 Targeted Imaging</i>	163
Cardiac Amyloidosis Imaging	163
CLINICAL IMPLEMENTATION CHALLENGES AND ECONOMIC CONSIDERATIONS	163
CHALLENGES AND FUTURE PERSPECTIVES	165
Regulatory and Economic Challenges	165
Technical and Scientific Challenges	165
Future Directions	166
CONCLUSION	166
DECLARATION	168
REFERENCES	168
CHAPTER 7 MOLECULAR NEUROIMAGING: WINDOWS INTO DEGENERATIVE PROCESSES	170
<i>Rajesh S. Kuber, Maajid Mohi Ud Din Malik and Mansour M. Alqahtani</i>	
INTRODUCTION	170
PET IMAGING OF AMYLOID AND TAU PROTEINS	172
Principles of PET Imaging	172
Amyloid PET Imaging	173
<i>Amyloid Pathology in Neurodegenerative Diseases</i>	173
<i>Amyloid PET Tracers</i>	173
<i>Clinical Applications of Amyloid PET</i>	173
CLINICAL IMPACT ANALYSIS	174
Tau PET Imaging	174
<i>Tau Pathology in Neurodegenerative Diseases</i>	174

<i>Tau PET Tracers</i>	175
<i>Clinical Applications of Tau PET</i>	175
CLINICAL SIGNIFICANCE AND PROGNOSTIC VALUE	176
EARLY Detection of Alzheimer's and Parkinson's Diseases	177
<i>Early Detection of Alzheimer's Disease</i>	177
<i>The Importance of Early Detection</i>	177
<i>Amyloid PET in Early AD Detection</i>	178
CONTEMPORARY CLINICAL EXAMPLES	178
Tau PET in Early AD Detection	179
Multimodal Approach to Early AD Detection	179
Early Detection of Parkinson's Disease	179
<i>Challenges in Early PD Detection</i>	180
<i>Dopaminergic System Imaging</i>	180
TREATMENT PLANNING IMPLICATIONS	181
Imaging Other Aspects of PD Pathology	182
Multimodal Approach to Early PD Detection	182
MONITORING DISEASE PROGRESSION AND TREATMENT RESPONSE	182
Monitoring Disease Progression	182
<i>Alzheimer's Disease Progression</i>	183
CLINICAL DECISION-MAKING CONTEXT	183
Parkinson's Disease Progression	184
Monitoring Treatment Response	185
THERAPEUTIC DECISION FRAMEWORK	185
Treatment Response in Alzheimer's Disease	186
Treatment Response in Parkinson's Disease	186
Challenges and Future Directions	186
CONCLUSION	187
REFERENCES	189
CHAPTER 8 ADVANCES IN PEDIATRIC NUCLEAR MEDICINE	190
<i>Purnachandra Kawdu Lamghare, Maajid Mohi Ud Din Malik and Mansour M. Alqahtani</i>	
INTRODUCTION	190
DOSE REDUCTION STRATEGIES	191
Novel Radiopharmaceuticals	192
CATEGORISATION AND CLINICAL IMPLICATIONS	192
99mTc-labeled Tracers	193
PET Tracers	193
Advanced Imaging Technologies	193
<i>Digital PET Detectors</i>	193
<i>Iterative Reconstruction Algorithms</i>	194
<i>Hybrid imaging</i>	194
Optimised Acquisition Protocols	194
<i>Weight-based Dosing</i>	194
<i>Time-based Protocols</i>	194
<i>Optimised Imaging Parameters</i>	195
Quality Assurance and Dose Tracking	195
<i>Dose Tracking Software</i>	196
<i>Diagnostic Reference Levels (DRLs)</i>	196
<i>Regular protocol review</i>	196
SPECIALISED PROTOCOLS FOR PEDIATRIC PATIENTS	196

Patient Preparation	196
PSYCHOLOGICAL CONSIDERATIONS AND EVIDENCE-BASED INTERVENTIONS	196
CLINICAL IMPLEMENTATION EXAMPLES:	197
Age-appropriate Education	198
Tailored Fasting and Hydration Protocols	198
Catheterisation and IV Access	198
Imaging Techniques	198
<i>Positioning Aids</i>	198
<i>Sedation and Anaesthesia Protocols</i>	198
<i>Respiratory Gating and Motion Correction</i>	199
Tailored Acquisition and Processing Protocols	199
Dynamic Imaging Protocols	199
SPECT/CT Protocols	199
PET/CT and PET/MRI Protocols	199
Quantification Methods	199
Reporting and Communication	199
<i>Structured Reporting</i>	200
<i>Multi-disciplinary Approach</i>	200
<i>Family-centred Communication</i>	200
RECENT APPLICATIONS IN PEDIATRIC ONCOLOGY AND NEUROLOGY	200
Pediatric Oncology	201
<i>PET/CT in Lymphoma</i>	201
STATISTICAL EVIDENCE AND COMPARATIVE ANALYSIS	201
MIBG Imaging in Neuroblastoma	202
CLINICAL IMPACT ANALYSIS	202
THERANOSTIC APPLICATIONS AND CLINICAL OUTCOMES	203
Novel PET Tracers in Pediatric Brain Tumours	204
Whole-body MRI with DWI and PET	204
Pediatric Neurology	204
<i>Epilepsy</i>	204
<i>Neurodevelopmental Disorders</i>	205
<i>Pediatric Movement Disorders</i>	205
<i>Neuroinflammatory Disorders</i>	205
<i>Emerging Applications</i>	206
<i>Theranostics in Pediatric Oncology</i>	206
<i>Artificial Intelligence in Pediatric Nuclear Medicine</i>	206
<i>Multimodal Imaging Approaches</i>	206
CONCLUSION	207
Regulatory and Access Challenges	208
Training and Workforce Development	208
Technological Integration and Standardisation	209
Economic Sustainability and Value Demonstration	209
Future Research Priorities	210
REFERENCES	210
CHAPTER 9 CARDIOVASCULAR NUCLEAR MEDICINE: BEYOND PERFUSION	212
<i>Aadil Rashid Malik, Maajid Mohi Ud Din Malik and Mansour M. Alqahtani</i>	
INTRODUCTION	213
MOLECULAR IMAGING OF ATHEROSCLEROSIS	213
PET Imaging of Plaque Inflammation	214
SPECT Imaging of Plaque Vulnerability	214

Hybrid Imaging: Combining Anatomy and Molecular Information	215
MULTIMODAL INTEGRATION	215
Future Directions and Clinical Implications	216
CLINICAL VALIDATION DISCUSSION	217
INNOVATIONS IN MYOCARDIAL VIABILITY ASSESSMENT	218
PET Imaging for Viability Assessment	218
<i>The Concept of PET Viability Imaging</i>	218
COMPARATIVE ANALYSIS	219
Advanced PET Protocols	220
Novel Molecular Targets for Viability Assessment	220
<i>Imaging Myocardial Innervation</i>	220
<i>Imaging Mitochondrial Function</i>	220
<i>Imaging Membrane Integrity</i>	221
Clinical Implications and Future Directions	221
NUCLEAR IMAGING IN HEART FAILURE MANAGEMENT	222
Evaluation of Left Ventricular Function and Volumes	222
Myocardial Perfusion Imaging in Heart Failure	222
CLINICAL DECISION-MAKING BASED ON PERFUSION IMAGING RESULTS	222
RISK-STRATIFIED MANAGEMENT PROTOCOLS	223
Ischemic vs. Non-ischemic Cardiomyopathy	224
Assessment of Myocardial Ischemia and Viability	224
Molecular Imaging in Heart Failure	225
<i>Sympathetic Innervation Imaging</i>	225
<i>Imaging Myocardial Metabolism</i>	225
<i>Imaging Myocardial Fibrosis and Remodelling</i>	225
Guiding Device Therapy in Heart Failure	225
<i>Phase Analysis in SPECT MPI</i>	225
<i>PET Imaging for CRT Optimisation</i>	226
Monitoring Therapy and Prognostication	226
<i>Serial Imaging for Treatment Monitoring</i>	226
<i>Risk Stratification</i>	226
FUTURE DIRECTIONS AND CHALLENGES	226
Emerging Technologies	226
<i>Novel Radiotracers</i>	226
<i>Advances in Instrumentation</i>	227
Integration with Other Imaging Modalities	227
Artificial Intelligence and Machine Learning Applications	227
IMAGE RECONSTRUCTION AND ENHANCEMENT	227
AUTOMATED DIAGNOSIS AND RISK STRATIFICATION	228
INTEGRATED MULTIMODAL ANALYSIS	228
CLINICAL IMPLEMENTATION AND WORKFLOW INTEGRATION	228
CHALLENGES AND FUTURE DIRECTIONS	229
Challenges and Limitations	229
CONCLUSION	229
DECLARATION	230
REFERENCES	230
CHAPTER 10 PRECISION ONCOLOGY AND RADIO-GUIDED SURGERY	233
<i>Maajid Mohi Ud Din Malik and Mansour M. Alqahtani</i>	
INTRODUCTION	234
Intraoperative Nuclear Imaging Techniques	236

Handheld Gamma Probes	236
Intraoperative Mobile Gamma Cameras	237
Cerenkov Luminescence Imaging	237
Radioguided Occult Lesion Localisation (ROLL)	237
ROBUST EMPIRICAL EVIDENCE	238
LONG-TERM OUTCOME VALIDATION	238
Fluorescence-Guided Surgery and Hybrid Approaches	239
SENTINEL LYMPH NODE MAPPING ADVANCEMENTS	239
Evolution of Sentinel Lymph Node Biopsy	240
Novel Radiotracers for Lymph Node Mapping	240
SPECT/CT in Preoperative Lymph Node Localisation	241
Intraoperative Navigation Systems	241
Sentinel Node Mapping in Various Cancer Types	241
CLINICAL PRACTICE TRANSFORMATION THROUGH ADVANCED SLN TECHNIQUES	243
HEAD AND NECK CANCER TRANSFORMATION	244
MELANOMA PRACTICE EVOLUTION	244
PROSTATE CANCER INNOVATION	245
TARGETED THERAPIES GUIDED BY NUCLEAR IMAGING	245
PRINCIPLES OF IMAGE-GUIDED THERAPY	245
PET/CT IN TREATMENT PLANNING AND RESPONSE ASSESSMENT	246
Theranostics: from Diagnosis to Therapy	246
LARGE-SCALE CLINICAL TRIAL VALIDATION AND LONG-TERM OUTCOMES	247
NETTER-1 TRIAL: PARADIGM-SHIFTING EVIDENCE IN NEUROENDOCRINE TUMOURS	247
VISION TRIAL: EXPANDING THERANOSTIC SUCCESS TO PROSTATE CANCER ...	248
ECONOMIC AND HEALTHCARE SYSTEM IMPACT ANALYSIS	248
Radionuclide Therapy and Dosimetry	249
Combination Therapies and Synergistic Approaches	249
CLINICAL APPLICATIONS AND CASE STUDIES	250
Breast Cancer	250
Melanoma	251
Prostate Cancer	251
Head and Neck Cancer	252
Neuroendocrine Tumours	252
FUTURE DIRECTIONS AND EMERGING TECHNOLOGIES	253
Intraoperative Molecular Imaging	254
Integration with Robotic Surgery	255
CHALLENGES AND LIMITATIONS	255
Technical Challenges	255
Technical Performance Limitations and Clinical Impact	256
Spatial Resolution Constraints in Small Lesion Detection	256
Partial Volume Effects and Quantification Accuracy	256
Motion Artefacts and Acquisition Limitations	257
Standardisation Challenges and Inter-Institutional Variability	257
Protocol Variability Impact on Outcomes	257
Regulatory and Economic Considerations	258
Training and Implementation	258
CONCLUSION	258
Quantified Clinical Impact and Future Potential	259
Critical Research Priorities and Knowledge Gaps	259

Standardisation and Implementation Imperatives	260
Technological Integration and Innovation Pathways	260
Call to Action for the Healthcare Community	260
Vision for Personalised Cancer Care	261
REFERENCES	261
CHAPTER 11 QUANTITATIVE SPECT AND PET: FROM RESEARCH TO CLINICAL PRACTICE	265
<i>Purnachandra Kawdu Lamghare, Maajid Mohi Ud Din Malik and Mansour M. Alqahtani</i>	
INTRODUCTION	266
STANDARDISATION OF QUANTITATIVE IMAGING	266
Calibration and Quality Control	267
Harmonization across Centers	267
CLINICAL IMPLEMENTATION CHALLENGES AND SOLUTIONS	267
CASE STUDY: MULTI-CENTRE 177LU DOSIMETRY STANDARDISATION	268
STAFF TRAINING AND COMPETENCY VALIDATION	268
ECONOMIC AND RESOURCE CONSIDERATIONS	269
Reconstruction and Correction Methods	269
Standardised Reporting	270
CLINICAL DECISION-MAKING FRAMEWORK FOR QUANTITATIVE METRICS	271
SUV APPROPRIATENESS AND LIMITATION ANALYSIS	271
ADVANCED VOLUMETRIC METRICS: CLINICAL VALIDATION AND APPLICATIONS	271
TREATMENT RESPONSE ASSESSMENT: METRIC-SPECIFIC APPLICATIONS	272
PERSONALISED THRESHOLD DEVELOPMENT	272
Challenges and Future Directions	273
APPLICATIONS IN TREATMENT RESPONSE ASSESSMENT	273
FDG-PET in Oncology	274
Beyond FDG: Novel PET Tracers	274
Quantitative SPECT in Treatment Response	275
Challenges and Future Directions	275
PHARMACOKINETIC MODELLING ADVANCEMENTS	276
Principles of Pharmacokinetic Modelling	277
Advancements in Image-Derived Input Functions	277
Simplified Kinetic Models	278
Parametric Imaging	278
SPECIFIC DEEP LEARNING FRAMEWORKS AND CLINICAL PERFORMANCE	279
VALIDATION AND ROBUSTNESS CONSIDERATIONS	280
Applications in Drug Development	280
Challenges and Future Directions	281
CONCLUSION	282
FUTURE CLINICAL INTEGRATION ANALYSIS	283
Artificial Intelligence Integration and Clinical Transformation	283
Real-Time Clinical Decision Support Systems	283
Personalized Treatment Optimization Frameworks	283
Regulatory and Implementation Challenges	284
Economic and Healthcare System Impact	284
REFERENCES	285
CHAPTER 12 RADIATION SAFETY AND DOSE OPTIMISATION	288
<i>Rajesh A. Kinshikar and Maajid Mohi Ud Din Malik</i>	

INTRODUCTION	289
NEW TECHNOLOGIES FOR RADIATION DOSE REDUCTION	290
Advanced Detector Technologies	290
CLINICAL IMPLEMENTATION CASE STUDIES AND QUANTITATIVE OUTCOMES	291
QUANTITATIVE PERFORMANCE METRICS IN CLINICAL PRACTICE	291
DIGITAL PET CLINICAL VALIDATION RESULTS	292
Novel Reconstruction Algorithms	292
Hybrid Imaging Modalities	293
Artificial Intelligence in Dose Reduction	293
PERSONALISED DOSIMETRY APPROACHES	294
From Population Models to Individual Assessments	294
QUANTITATIVE IMPACT OF PATIENT-SPECIFIC FACTORS ON DOSIMETRY	
CALCULATIONS	295
BODY WEIGHT AND SURFACE AREA CORRELATIONS:	295
BMI AND BODY COMPOSITION EFFECTS	296
ORGAN SIZE AND ANATOMICAL VARIATIONS	296
PHYSIOLOGICAL FUNCTION VARIATIONS	296
Advanced Imaging Techniques for Dosimetry	297
Computational Methods and Monte Carlo Simulations	297
Biokinetic Modelling and Dose Calculation	298
REGULATORY UPDATES AND BEST PRACTICES	299
International Guidelines and Standards	300
COMPARATIVE ANALYSIS OF INTERNATIONAL REGULATORY	
IMPLEMENTATION	300
DOSE LIMIT VARIATIONS AND IMPLEMENTATION STRATEGIES	301
PATIENT DOSE REGULATION: DIAGNOSTIC REFERENCE LEVELS	
IMPLEMENTATION	301
QUANTITATIVE COMPARISON OF DRL VALUES ACROSS JURISDICTIONS	302
REGULATORY APPROACH TO EMERGING TECHNOLOGIES	302
INTERNATIONAL COOPERATION AND HARMONISATION EFFORTS	302
Implementing the ALARA Principle	303
Radiation Protection for Patients	303
Occupational Radiation Protection	304
Environmental and Public Safety Considerations	304
FUTURE DIRECTIONS AND CHALLENGES	305
Evidence-Based Implementation Strategies and Measurable Outcomes	307
Systematic Technology Adoption Framework:	307
Cost-Effectiveness Validation Studies:	307
Quality Metrics and Performance Indicators	308
Long-Term Outcome Validation	308
CONCLUSION	309
DECLARATION	310
REFERENCES	310
CHAPTER 13 THERANOSTICS BEYOND ONCOLOGY	313
<i>Mansour M. Alqahtani, Maajid Mohi Ud Din Malik and Ajai Kumar Shukla</i>	
INTRODUCTION	314
EMERGING APPLICATIONS IN RHEUMATOLOGY	315
Molecular Targets in Rheumatology	315
Diagnostic Applications	316
Therapeutic Applications	316

CLINICAL EVIDENCE AND REAL-WORLD IMPLEMENTATION	317
CASE STUDY: FOLATE-TARGETED METHOTREXATE DELIVERY	317
QUANTITATIVE CLINICAL OUTCOMES ANALYSIS	317
Challenges and Future Directions	318
NUCLEAR MEDICINE IN INFECTIOUS DISEASES	319
Molecular Imaging of Infection	319
Theranostic Applications in Infectious Diseases	320
POINT-OF-CARE IMPLEMENTATION: CHALLENGES AND SOLUTIONS	320
TECHNICAL IMPLEMENTATION CHALLENGES	320
REGULATORY AND TRAINING BARRIERS	321
CLINICAL IMPLEMENTATION MODELS	321
Challenges and Opportunities	322
POTENTIAL USES IN PSYCHIATRIC DISORDERS	322
Molecular Imaging in Psychiatry	323
Theranostic Concepts in Psychiatry	324
Challenges and Future Directions	324
Ethical Considerations and Patient Perspectives	325
EMPIRICAL EVIDENCE FOR PATIENT EMPOWERMENT AND CLINICAL OUTCOMES	326
QUANTITATIVE MEASURES OF PATIENT EMPOWERMENT	326
TREATMENT ADHERENCE AND CLINICAL OUTCOMES	327
QUALITATIVE PATIENT PERSPECTIVES	327
Integration with Existing Psychiatric Practice	327
COMPARATIVE ANALYSIS OF THERANOSTIC APPLICATIONS	328
Target Specificity	328
Translation from Diagnostics to Therapeutics	328
Clinical Implementation Challenges	328
Potential Impact	329
FUTURE DIRECTIONS AND CHALLENGES	329
Technological Advancements	329
Regulatory and Economic Considerations	329
PRACTICAL IMPLEMENTATION BARRIERS AND HEALTHCARE SYSTEM INTEGRATION	330
HEALTHCARE PROFESSIONAL TRAINING AND COMPETENCY DEVELOPMENT	330
INSTITUTIONAL INFRASTRUCTURE AND WORKFLOW INTEGRATION	330
REIMBURSEMENT AND HEALTH ECONOMICS BARRIERS	331
REGULATORY PATHWAY COMPLEXITY	331
Personalised Medicine and Big Data	332
Ethical and Social Implications	332
CONCLUSION	332
Current State of Evidence and Research Gaps	333
Emerging Research Priorities and Future Directions	333
Transformative Potential and Long-term Vision	334
REFERENCES	335
CHAPTER 14 NUCLEAR MEDICINE IN THE ERA OF PRECISION MEDICINE	337
<i>Rajesh S Kuber, Maajid Mohi Ud Din Malik and Mansour M. Alqahtani</i>	
INTRODUCTION	338
INTEGRATION WITH GENOMICS AND PROTEOMICS	338
The Promise of Multi-Omics Integration	338
Genomics and Nuclear Medicine	339

Proteomics and Nuclear Medicine	339
MASS SPECTROMETRY METHODOLOGIES AND CLINICAL TRANSLATION	339
TECHNICAL IMPLEMENTATION AND CLINICAL WORKFLOW	340
Theranostics and Genomics	340
QUANTITATIVE CLINICAL OUTCOMES AND EVIDENCE-BASED	
IMPLEMENTATION	341
INTERIM PET IN LYMPHOMA: QUANTITATIVE OUTCOMES ANALYSIS	341
GENOMIC BIOMARKERS AND TREATMENT RESPONSE QUANTIFICATION	342
REAL-WORLD IMPLEMENTATION AND HEALTH ECONOMICS	342
Challenges and Future Directions	342
RADIOMICS AND TEXTURE ANALYSIS	344
Principles of Radiomics	344
Applications in Nuclear Medicine	344
<i>Tumour Characterisation</i>	344
DETAILED CASE STUDIES: GENE MUTATION-IMAGING PATTERN	
CORRELATIONS	345
CASE STUDY 1: NSCLC EGFR MUTATIONS AND FDG-PET PATTERNS	345
CASE STUDY 2: PROSTATE CANCER GENOMIC ALTERATIONS AND PSMA	
EXPRESSION	345
CASE STUDY 3: GLIOBLASTOMA IDH MUTATIONS AND AMINO ACID PET	346
Treatment Response Prediction	346
Prognostication	347
Challenges and Future Directions	347
PERSONALISED TREATMENT PLANNING AND MONITORING	349
Personalised Treatment Planning	349
<i>Target Identification and Characterisation</i>	349
<i>Treatment Selection and Optimisation</i>	349
Personalised Treatment Monitoring	350
<i>Early Response Assessment</i>	350
Thematic Patterns in Early Response Assessment Across Cancer Types	350
Pattern 1: Metabolic Response Heterogeneity and Treatment Resistance	351
Clinical Application Framework	351
Pattern 2: Temporal Response Kinetics and Therapeutic Mechanism	351
Cross-Cancer Validation Studies	352
Pattern 3: Spatial Response Patterns and Anatomical Considerations	352
Anatomical Response Modifiers	352
Pattern 4: Integration with Circulating Biomarkers	352
Universal Implementation Framework	352
<i>Treatment Adaptation</i>	353
<i>Long-term Surveillance</i>	353
CHALLENGES AND FUTURE DIRECTIONS	354
CRITICAL ANALYSIS OF IMPLEMENTATION FAILURES AND TECHNOLOGICAL	
LIMITATIONS	355
ARTIFICIAL INTELLIGENCE IMPLEMENTATION CHALLENGES AND ETHICAL	
CONSIDERATIONS	355
ALGORITHMIC BIAS AND HEALTH DISPARITIES	356
INTERPRETABILITY AND CLINICAL RESPONSIBILITY	356
CLINICAL IMPLEMENTATION FAILURES AND LESSONS LEARNED	356
SPECIFIC NUCLEAR MEDICINE IMPLEMENTATION CHALLENGES	357
Radiomics Reproducibility Crisis	357
Theranostic Scaling Challenges	357

Cost-Effectiveness Validation Failures	357
FUTURE DEVELOPMENT PRIORITIES AND RISK MITIGATION	357
Diverse Dataset Development	357
Explainable AI Research	358
Implementation Science Integration	358
CONCLUSION	358
Recent Advances in Immunotherapy Response Assessment	358
Emerging Technologies and Future Paradigms	359
Multi-omics Integration and Systems Medicine	359
Challenges and Realistic Assessment	359
Long-term Vision and Societal Impact	360
Call for Continued Innovation and Collaboration	360
DECLARATION	361
REFERENCES	361
CHAPTER 15 FUTURE HORIZONS IN NUCLEAR MEDICINE	364
<i>Mansour M. Alqahtani and Maajid Mohi Ud Din Malik</i>	
INTRODUCTION	364
EMERGING TECHNOLOGIES ON THE HORIZON	365
Next-Generation Imaging Systems	365
<i>Total-Body PET Scanners</i>	365
COMPARATIVE PERFORMANCE ANALYSIS: NEXT-GENERATION VS. CURRENT TECHNOLOGIES	366
TOTAL-BODY PET: QUANTITATIVE PERFORMANCE COMPARISONS	366
ADVANCED SPECT TECHNOLOGIES: PERFORMANCE VALIDATION	367
Advanced SPECT Technologies	367
Hybrid and Multimodality Imaging	367
Advanced Image Reconstruction and Analysis	368
<i>Artificial Intelligence in Image Reconstruction</i>	368
<i>Radiomics and Texture Analysis</i>	368
Novel Radiopharmaceuticals and Theranostic Agents	368
Radionuclide Production and Handling	369
POTENTIAL IMPACTS OF QUANTUM COMPUTING AND NANOTECHNOLOGY	369
Quantum Computing in Nuclear Medicine	370
<i>Image Reconstruction and Analysis</i>	370
<i>Treatment Planning and Dosimetry</i>	371
<i>Data Security and Management</i>	371
Nanotechnology in Nuclear Medicine	371
<i>Nanoparticle-Based Imaging Agents</i>	371
<i>Nanoparticle-Mediated Radionuclide Therapy</i>	372
<i>Nanosensors and Theranostics</i>	372
DETAILED CASE STUDIES: CLINICAL TRANSLATION OF NANOTECHNOLOGY APPLICATIONS	373
CASE STUDY 1: 225AC-PSMA-617 TARGETED ALPHA THERAPY	373
CASE STUDY 2: WERNER ET AL. NANOPARTICLE-MEDIATED COMBINATION THERAPY	374
CASE STUDY 3: CHEN ET AL. MULTIMODAL NANOPARTICLE PLATFORM	375
ETHICAL CONSIDERATIONS AND PATIENT-CENTRIC ADVANCEMENTS	375
Ethical Considerations in Advanced Nuclear Medicine	376
<i>Privacy and Data Security</i>	376
<i>Equitable Access to Advanced Technologies</i>	376

<i>Responsible Innovation</i>	376
PRACTICAL ETHICAL IMPLEMENTATION FRAMEWORKS AND REAL-WORLD APPLICATIONS	377
FRAMEWORK 1: MAYO CLINIC EMERGING TECHNOLOGY ETHICS PROTOCOL	377
Data Privacy and Security Implementation	377
Equitable Access Implementation Strategy	377
FRAMEWORK 2: EU RESPONSIBLE RESEARCH AND INNOVATION (RRI) MODEL FOR NUCLEAR MEDICINE	378
Stakeholder Engagement Protocols	378
Anticipatory Ethics Implementation	378
FRAMEWORK 3: SINGAPORE NATIONAL HEALTHCARE AI ETHICS BOARD NUCLEAR MEDICINE GUIDELINES	379
Transparency and Explainability Requirements	379
Equity Monitoring and Correction Protocols	379
Patient-Centric Advancements	380
<i>Personalised Medicine and Patient Empowerment</i>	380
<i>Minimising Patient Burden</i>	380
<i>Improving Patient Experience</i>	381
<i>Ethical Framework for Future Nuclear Medicine</i>	381
CONCLUSION	382
Immediate Policy Recommendations for Healthcare Institutions	382
Regulatory and Professional Society Action Items	383
<i>International Collaboration and Standardisation Initiatives</i>	383
<i>Call to Action for the Nuclear Medicine Community</i>	384
<i>Long-Term Vision and Sustained Commitment</i>	385
DECLARATION	385
REFERENCES	385
SUBJECT INDEX	387

FOREWORD

Nuclear medicine stands as one of the most rapidly evolving fields in modern healthcare, representing a unique convergence of physics, chemistry, biology, and clinical medicine. The discipline's ability to visualize and quantify biological processes at the molecular level has revolutionized our understanding of human disease and transformed therapeutic approaches across multiple medical specialties. It is therefore with great pleasure that I introduce this comprehensive book, "**Molecular Imaging Advances: Cutting-Edge Developments in Nuclear Medicine**," expertly edited by Dr. Maajid Mohi Ud Din Malik and Dr. Mansour M. Alqahtani.

The timing of this publication could not be more opportune. We are witnessing an unprecedented acceleration in technological innovation within nuclear medicine, driven by advances in detector technology, artificial intelligence, radiopharmaceutical development, and computational methods. These developments are not merely incremental improvements but represent paradigm shifts that are fundamentally changing how we diagnose, monitor, and treat disease. This book captures these transformative developments with remarkable clarity and depth.

What distinguishes this work is its comprehensive scope and practical relevance. The editors have assembled a distinguished group of international contributors who bring diverse perspectives and expertise to each chapter. From the foundational concepts presented in the opening chapters to the cutting-edge applications of theranostics and artificial intelligence, the book maintains a careful balance between theoretical understanding and clinical application. The inclusion of case studies, practical examples, and discussions of implementation challenges makes this volume particularly valuable for practitioners seeking to translate these advances into patient care.

The book's treatment of emerging technologies is particularly noteworthy. The chapters on total-body PET imaging, novel radiopharmaceuticals, and AI-driven image analysis provide readers with insights into technologies that will shape the future of nuclear medicine. Equally important is the attention given to practical considerations such as radiation safety, dose optimization, and regulatory compliance—aspects often overlooked in purely technical discussions but essential for successful clinical implementation.

The emphasis on personalized medicine throughout the book reflects one of the most significant trends in modern healthcare. The detailed exploration of theranostics—the seamless integration of diagnostic imaging and targeted therapy—illustrates how nuclear medicine is leading the charge toward truly personalized treatment approaches. The authors effectively demonstrate how advances in molecular imaging are enabling clinicians to select the right treatment for the right patient at the right time.

For medical students, residents, and practicing physicians, this book serves as both an educational resource and a practical guide. For researchers and industry professionals, it provides valuable insights into current challenges and future opportunities. The clear writing style and logical organization make complex concepts accessible without sacrificing scientific rigor.

As we look toward the future of nuclear medicine, it is clear that we are entering an era of unprecedented opportunity. The integration of artificial intelligence, the development of novel radiopharmaceuticals, and the expanding applications of hybrid imaging are opening new

ii

frontiers in patient care. This book provides readers with the knowledge and perspective needed to navigate and contribute to these exciting developments.

I commend the editors and contributors for their dedication to advancing the field through education and knowledge sharing. This volume will undoubtedly serve as a valuable reference for years to come, inspiring the next generation of nuclear medicine professionals to push the boundaries of what is possible in molecular imaging and targeted therapy.

Essam M. Alkhybari
Associate Professor Nuclear Medicine
Department of Radiology and Medical Imaging
College of Applied Medical Sciences
Prince Sattam Bin Abdulaziz University
Al-Kharj, Saudi Arabia

PREFACE

Nuclear medicine stands at the forefront of modern healthcare, offering unprecedented insights into human physiology and pathology at the molecular level. The past decade has witnessed remarkable advancements in this field, transforming both diagnostic imaging and therapeutic approaches across medical specialties. "Molecular Imaging Advances: Cutting-Edge Developments in Nuclear Medicine" aims to provide a comprehensive exploration of these revolutionary developments and their impact on clinical practice and research.

This book represents a collaborative effort among leading experts in nuclear medicine, medical physics, radiochemistry, and related disciplines. It serves dual purposes: as an educational resource for trainees and as a reference guide for established professionals navigating the rapidly evolving landscape of nuclear medicine.

The chapters within this volume span a broad spectrum of topics, reflecting the multifaceted nature of recent innovations in the field. From next-generation PET and SPECT technologies to novel radiopharmaceuticals, and from groundbreaking applications of artificial intelligence to advances in theranostics, each chapter provides detailed coverage of both theoretical foundations and practical implementations, while also examining future prospects.

Key focus areas include technological advancements in imaging systems and reconstruction algorithms, emerging radiopharmaceuticals for diagnosis and therapy, the integration of artificial intelligence and machine learning in image analysis, personalized medicine approaches including theranostics and precision oncology, advances in pediatric nuclear medicine and neuroimaging, quantitative imaging techniques for treatment response assessment, and radiation safety and dose optimization strategies.

Throughout this book, we have maintained a careful balance between technical depth and clinical relevance, ensuring that readers from various backgrounds can appreciate the significance of these developments. Case studies, practical examples, and discussions of ongoing research provide context and demonstrate the real-world impact of these innovations.

As editors, we express our sincere gratitude to all contributors who have shared their expertise and insights, making this comprehensive volume possible. Their dedication to advancing the field of nuclear medicine is evident in the quality and depth of each chapter.

We anticipate that this book will not only serve as a valuable resource for current practitioners but also inspire the next generation of researchers and clinicians to push the boundaries of what is possible in molecular imaging and targeted radiotherapy. As we look to the future, it is clear that nuclear medicine will continue to play a pivotal role in advancing patient care, and we are privileged to be part of this exciting journey.

Maajid Mohi Ud Din Malik

Dr. D.Y. Patil School of Allied Health Sciences
Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University)
Sant Tukaram Nagar, Pune, Maharashtra, India

&

Mansour M. Alqahtani

Department of Radiological Sciences
College of Applied Medical Sciences
Najran University, Najran, Saudi Arabia

List of Contributors

- Ajai Kumar Shukla** Department of Nuclear Medicine, Dr. Ram Manohar Lohia Institute of Medical Sciences, Vibhuti-Khand, Gomti Nagar, Lucknow, India
- Aadil Rashid Malik** Department of Radiology and Imaging Technology, CT University, Ludhiana, Punjab, India
- Mansour M. Alqahtani** Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia
- Maajid Mohi Ud Din Malik** Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India
- Rajesh A Kinhikar** Department of Medical Physics, Dr. D.Y. Patil Medical College, Hospital And Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune (Deemed to be University)- Sant Tukaram Nagar, Pune, India
- Kuber Rajesh S** Department of Radio-Diagnosis, Dr. D.Y. Patil Medical College, Hospital And Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune (Deemed to be University)- Sant Tukaram Nagar, Pune, India
- Purnachandra Kawdu Lamghare** Department of Radio-Diagnosis, Dr. D.Y. Patil Medical College, Hospital And Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune (Deemed to be University)- Sant Tukaram Nagar, Pune, India

CHAPTER 1**Nuclear Medicine: Essential Concepts and Applications****Maajid Mohi Ud Din Malik^{1,*} and Mansour M. Alqahtani²**

¹ *Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India*

² *Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia*

Abstract: Nuclear medicine has undergone remarkable advancements in recent years, revolutionising diagnostic and therapeutic approaches in various medical fields. This chapter provides a comprehensive overview of the current state and recent breakthroughs in nuclear medicine. We explore the evolution of imaging technologies, including the development of total-body PET systems, which offer unprecedented sensitivity and the ability to perform ultra-low-dose whole-body scans. The emergence of novel radiopharmaceuticals, such as PSMA-targeted agents for prostate cancer and fibroblast activation protein inhibitors (FAPIs) for various cancers, has significantly enhanced diagnostic accuracy and opened new avenues for targeted therapies. The field of theranostics, exemplified by using lutetium-177-labelled agents for neuroendocrine tumours and prostate cancer, represents a paradigm shift towards more personalized and effective treatments. Advances in neuroimaging, particularly the development of tau PET tracers and synaptic density imaging, have provided unprecedented insights into neurodegenerative diseases. Introducing alpha-emitting radionuclides in targeted therapies offers new hope for patients with advanced cancers. Furthermore, significant progress in quantitative SPECT has expanded its applications, especially in dosimetry for radionuclide therapies. Integrating artificial intelligence and machine learning in image analysis and treatment planning is poised to further enhance the precision and efficiency of nuclear medicine procedures. These developments collectively underscore the pivotal role of nuclear medicine in advancing precision medicine, offering more accurate diagnoses, personalised treatments, and improved patient outcomes across a broad spectrum of diseases.

Keywords: Alpha-emitter therapy, Novel radiopharmaceuticals, Quantitative SPECT, Theranostics, Total-body PET.

* **Corresponding author Maajid Mohi Ud Din Malik:** Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India; E-mail: majidmalik343@gmail.com

Maajid Mohi Ud Din Malik & Mansour M. Alqahtani (Eds.)
All rights reserved-© 2025 Bentham Science Publishers

HISTORICAL PERSPECTIVE

The Birth of Nuclear Medicine

The story of nuclear medicine begins in the early 20th century, intertwined with the discovery of radioactivity and the development of atomic physics (Table 1). In 1896, Henri Becquerel accidentally discovered radioactivity while working with uranium salts, laying the groundwork for future developments in the field [1]. Shortly after, Marie and Pierre Curie isolated radium and polonium, further advancing our understanding of radioactive elements [2].

The medical applications of radioactivity were recognised early on. In 1913, George de Hevesy developed the tracer principle, using radioactive isotopes to study plant chemical processes. This principle would later become fundamental to nuclear medicine [3]. The first human use of artificial radioactivity for medical purposes occurred in 1936 when John Lawrence treated leukaemia patients with phosphorus-32 [4].

Table 1. Historical perspective of nuclear medicine.

Year	Event	Significance
1895	Discovery of X-rays by Wilhelm Röntgen	Laid the foundation for medical imaging
1896	Discovery of radioactivity by Henri Becquerel	Introduced the concept of radioactivity
1898	Isolation of radium and polonium by Marie and Pierre Curie	Expanded understanding of radioactive elements
1913	Development of the radioactive tracer principle by Georg de Hevesy	Established the basis for nuclear medicine techniques
1927	Introduction of the cyclotron by Ernest Lawrence	Enabled the production of artificial radioisotopes
1934	Artificial radioactivity was discovered by Irène and Frédéric Joliot-Curie	Opened possibilities for creating medical isotopes
1936	The first therapeutic use of artificial radioiodine by John Lawrence	Marked the beginning of targeted radionuclide therapy
1946	Distribution of radioisotopes for medical use begins	Expanded access to radioisotopes for medical applications
1951	First diagnostic use of iodine-131 for thyroid imaging	Demonstrated the potential of nuclear imaging
1958	Development of the gamma camera by Hal Anger	Revolutionised nuclear imaging capabilities
1962	Introduction of technetium-99m as a medical tracer	Became the most widely used radioisotope in nuclear medicine
1963	Development of technetium-99m generators	Improved availability of short-lived radioisotopes

(Table 1) cont....

Year	Event	Significance
1970s	Introduction of Single Photon Emission Computed Tomography (SPECT)	Enabled 3D imaging of radioisotope distribution
1973	Development of Positron Emission Tomography (PET) by Michael Ter-Pogossian and colleagues	Introduced high-sensitivity functional imaging
1990s	Introduction of PET/CT hybrid imaging	Combined functional and anatomical imaging
2000s	Development of PET/MRI systems	Further advanced multimodal imaging capabilities
2010s	Introduction of digital PET detectors	Improved sensitivity and image quality
2019	First human imaging with total-body PET	Marked a new era in whole-body molecular imaging

Post-World War II Developments

The end of World War II marked a significant turning point for nuclear medicine. The Manhattan Project led to the development of nuclear reactors, which could produce a wide range of radioisotopes. In 1946, the U.S. Atomic Energy Commission began distributing radioisotopes for medical use, greatly expanding the field's potential [5].

The 1950s saw rapid advancements in nuclear medicine instrumentation. Hal Anger invented the gamma camera in 1957, revolutionising nuclear imaging by allowing visualisation of radioisotope distribution in the body [5]. This period also saw the development of technetium-99m generators by Walter Tucker and Margaret Greene, providing a convenient source of short-lived radioisotopes for medical use.

The Rise of Molecular Imaging

The 1970s and 1980s brought about significant advances in imaging technology and radiopharmaceuticals. The introduction of single-photon emission computed tomography (SPECT) in the early 1970s allowed for three-dimensional imaging of radioisotope distribution. This was followed by the development of positron emission tomography (PET) in the mid-1970s, which offered even greater sensitivity and resolution [6].

The concept of molecular imaging emerged in the 1990s, focusing on visualising cellular and molecular processes in living organisms. This approach has been compelling in oncology, neurology, and cardiology, allowing for earlier disease detection and more personalised treatment approaches.

Next-Generation PET Imaging Technologies

Mansour M. Alqahtani^{1,*} and Maajid Mohi Ud Din Malik²

¹ Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

Abstract: Positron Emission Tomography (PET) has undergone significant advancements in recent years, revolutionising molecular imaging in clinical and research settings. This chapter provides a comprehensive overview of next-generation PET technologies, focusing on three key areas: advancements in PET scanner design, time-of-flight (TOF) PET, and total-body PET imaging. Recent developments in detector technology, including the adoption of silicon photomultipliers and fast scintillators, have enabled improved spatial resolution, sensitivity, and timing performance. Time-of-flight PET, which measures the difference in arrival times of annihilation photons, offers enhanced image quality and signal-to-noise ratio, which is particularly beneficial for larger patients and challenging imaging scenarios. The groundbreaking concept of total-body PET, extending the axial field of view to cover the entire human body, provides unprecedented sensitivity and enables dynamic whole-body imaging, opening new avenues for research and clinical applications. These technological advancements are complemented by the integration of artificial intelligence in image reconstruction and analysis, further enhancing the capabilities of PET imaging. The chapter also explores the evolution of multimodal imaging, mainly PET/CT and PET/MRI, and their impact on diagnostic accuracy and research potential. While these next-generation technologies offer significant benefits in improved lesion detectability, reduced scan times, and lower radiation doses, they also present challenges related to cost, complexity, and clinical implementation. The chapter concludes by discussing emerging trends and future perspectives, including theranostics, personalised imaging protocols, and the potential impact of quantum technologies on PET imaging.

Keywords: Artificial intelligence, Multimodal imaging, Positron emission tomography, Time-of-flight PET, Total-body PET.

* **Corresponding author Mansour M. Alqahtani:** Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia; E-mail: mmalqahtane@nu.edu.sa

INTRODUCTION

Positron Emission Tomography (PET) has revolutionised medical imaging since its inception in the 1970s. As a functional imaging modality, PET provides unique insights into physiological and pathological processes at the molecular level, making it an invaluable tool in oncology, neurology, cardiology, and various other medical fields. Over the past few decades, PET technology has undergone significant advancements, driven by improvements in detector technology, image reconstruction algorithms, and our understanding of tracer kinetics.

This chapter focuses on the next generation of PET imaging technologies that are shaping the future of molecular imaging. We will explore three main areas of advancement: overall improvements in PET scanner design, developing and implementing time-of-flight (TOF) PET, and the groundbreaking concept of total-body PET imaging. These innovations promise to enhance image quality, reduce scan times and radiation doses, and open new avenues for research and clinical applications.

As we delve into these topics, we will examine each advancement's underlying principles, technological challenges, and potential benefits. We will also discuss their impact on clinical practice and research, as well as the economic and practical considerations for their implementation. By the end of this chapter, readers will have a comprehensive understanding of the current state of PET technology and a glimpse into its exciting future.

ADVANCEMENTS IN PET SCANNER DESIGN

Evolution of Detector Technology

The heart of any PET scanner is its detector system. Over the years, advancements in detector technology have led to improved performance and image quality (Table 1).

Table 1. Comparison of key PET detector technologies.

Feature	PMT-Based Detectors	SiPM-Based Detectors
Size	Bulky	Compact
Magnetic Field Sensitivity	Sensitive	Insensitive
Timing Resolution	Good	Excellent
Quantum Efficiency	Moderate	High
Cost	Moderate	Higher (but decreasing)
MRI Compatibility	Poor	Excellent

Scintillation Crystals

Early PET scanners used sodium iodide (NaI) crystals, but newer materials have replaced these with superior properties. Bismuth germanate (BGO) became popular due to its high stopping power for 511 keV photons. However, its relatively slow decay time limited its use in fast PET systems.

Lutetium oxyorthosilicate (LSO) and its cerium-doped variant (LSO: Ce) have emerged as the scintillators of choice for many modern PET systems. These crystals offer a combination of high light output, fast decay time, and good stopping power. More recently, lutetium-yttrium oxyorthosilicate (LYSO) has gained popularity as it shares many of the favourable properties of LSO while being somewhat easier to grow in large quantities. Melcher (2000) notes that these lutetium-based scintillators have been crucial in developing time-of-flight PET and other advanced PET technologies [1].

Photosensors

Traditionally, photomultiplier tubes (PMTs) have been used to detect the scintillation light produced by gamma-ray interactions in the crystals. PMTs offer high gain and low noise but are bulky and sensitive to magnetic fields, making them unsuitable for integrated PET/MRI systems.

In recent years, there has been a shift towards solid-state photosensors, particularly silicon photomultipliers (SiPMs). As highlighted by Acerbi and Gundacker (2019), SiPMs offer several advantages over traditional PMTs:

1. Compact size, allowing for more flexible detector designs
2. Insensitivity to magnetic fields, enabling their use in PET/MRI systems
3. Higher quantum efficiency, potentially improving system sensitivity
4. Excellent timing resolution, crucial for time-of-flight PET [2]

The adoption of SiPMs has been a critical enabler for many recent advancements in PET technology, including digital PET systems and improved time-of-flight capabilities.

Improvements in Spatial Resolution

Spatial resolution in PET imaging has seen steady improvements over the years, driven by advancements in both hardware and software.

CHAPTER 3**SPECT/CT and PET/CT: Hybrid Imaging Innovations****Maajid Mohi Ud Din Malik^{1*} and Mansour M. Alqahtani²**

¹ *Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India*

² *Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia*

Abstract: Nuclear medicine has witnessed remarkable advancements in recent years, particularly in hybrid imaging technologies. Single-photon emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography/computed tomography (PET/CT) have emerged as powerful diagnostic tools, combining the high sensitivity of nuclear imaging with the anatomical precision of CT. This chapter provides a comprehensive overview of the technological improvements in these hybrid imaging modalities, their clinical applications, and future directions. We explore the evolution of detector technology, image reconstruction algorithms, and quantification methods that significantly enhance image quality and diagnostic accuracy. The clinical impact of hybrid imaging across various medical specialties, including oncology, cardiology, and neurology, is discussed in detail. Furthermore, we examine emerging technologies such as PET/MRI, total-body PET, and the integration of artificial intelligence in hybrid imaging. The chapter also addresses the challenges and opportunities in the field, emphasising the role of interdisciplinary collaboration and the potential of these advanced imaging modalities in advancing personalised medicine and precision health.

Keywords: Artificial intelligence, Hybrid imaging, Molecular imaging, Quantitative imaging, SPECT/CT, PET/CT, Theranostics.

INTRODUCTION

Nuclear medicine has witnessed remarkable advancements in recent years, particularly in hybrid imaging technologies. Single-photon emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography/computed tomography (PET/CT) have emerged as

* **Corresponding author Maajid Mohi Ud Din Malik:** Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India; E-mail: majidmalik343@gmail.com

powerful diagnostic tools, combining the high sensitivity of nuclear imaging with the anatomical precision of CT. This synergistic approach has revolutionised medical imaging, offering unprecedented insights into the structure and function of organs and tissues within the human body [1].

The journey of hybrid imaging began in the late 1990s with the development of Townsend and colleagues' first PET/CT prototype. This innovation addressed a critical need in medical imaging: the precise co-registration of functional and anatomical information. Before hybrid systems, clinicians had to mentally fuse images from separate modalities, a time-consuming process prone to errors. Introducing hybrid imaging systems eliminated this challenge, providing perfectly aligned functional and anatomical images in a single examination.

SPECT/CT, following closely on the heels of PET/CT, brought similar benefits to single-photon emitting radiopharmaceuticals. This development was particularly significant for nuclear medicine departments primarily utilising SPECT imaging. The integration of CT with SPECT improved image quality through attenuation correction and enhanced diagnostic confidence by providing anatomical context to functional abnormalities [2].

The impact of these hybrid imaging modalities has been profound across various medical specialities. PET/CT has become an indispensable tool for cancer staging, treatment planning, and response assessment in oncology. The ability to detect metabolic changes often before anatomical changes are apparent has revolutionised early cancer detection and management strategies [3]. In cardiology, hybrid imaging has significantly improved the assessment of coronary artery disease and myocardial viability, leading to more accurate diagnoses and tailored treatment plans [4]. Neurological applications have also benefited greatly, with hybrid imaging crucial in evaluating neurodegenerative disorders, epilepsy, and brain tumours [5].

The technological evolution of hybrid imaging systems has been rapid and continuous. Advancements in detector technology, such as introducing solid-state detectors in SPECT and silicon photomultipliers in PET, have dramatically improved image quality and quantitative accuracy. Innovations in CT technology, including integrating multi-slice CT scanners and developing iterative reconstruction algorithms, have enhanced anatomical detail while reducing radiation exposure [6].

As we delve deeper into this chapter, we will explore the technological improvements that have driven the evolution of SPECT/CT and PET/CT systems. We will examine the expanding range of clinical applications across various medical specialities, highlighting how these hybrid imaging modalities have

transformed diagnostic approaches and patient management strategies. Furthermore, we will look towards the future, discussing emerging technologies such as PET/MRI and the potential impact of artificial intelligence on hybrid imaging.

The field of hybrid imaging stands as a testament to the power of interdisciplinary collaboration, bringing together experts in nuclear medicine, radiology, physics, and engineering. As we continue to push the boundaries of what is possible in medical imaging, hybrid systems like SPECT/CT and PET/CT will undoubtedly play a central role in shaping the future of personalised medicine, offering increasingly precise and comprehensive insights into human health and disease.

TECHNOLOGICAL IMPROVEMENTS IN HYBRID SYSTEMS

Technological innovations across multiple fronts have driven the rapid evolution of SPECT/CT and PET/CT systems. These advancements have significantly enhanced image quality, quantitative accuracy, and overall diagnostic performance, pushing the boundaries of what is possible in molecular imaging (Table 1).

Table 1. Comparison of traditional and advanced SPECT/CT systems.

Feature	Traditional SPECT/CT	Advanced SPECT/CT
Detector	NaI scintillation crystal	CZT solid-state detector
Energy Resolution	9-10%	5-6%
Sensitivity	Standard	5-10x improvement
Spatial Resolution	7-9 mm	4-6 mm
Acquisition Time	15-20 minutes	3-5 minutes
CT Component	Single or dual-slice	16-128 slice
Quantification	Limited	Absolute quantification possible

SPECT/CT Advancements

SPECT/CT technology has improved remarkably since its introduction, enhancing image quality and diagnostic capabilities. Key advancements include:

1. **Detector Technology:** The development of solid-state detectors, particularly cadmium zinc telluride (CZT), has marked a paradigm shift in SPECT imaging. CZT detectors offer superior energy resolution (5-6% compared to 9-10% for traditional NaI crystals) and significantly improved sensitivity. This enhancement allows for better discrimination between different radionuclides

The AI Revolution in Nuclear Medicine

Mansour M. Alqahtani^{1,*} and Maajid Mohi Ud Din Malik²

¹ Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

Abstract: Artificial Intelligence (AI) is revolutionising nuclear medicine, offering unprecedented opportunities to enhance image quality, improve diagnostic accuracy, and optimise treatment planning. This chapter provides a comprehensive overview of AI's current applications and prospects in nuclear medicine. We begin by exploring AI-assisted image reconstruction and analysis techniques, which enable the generation of high-quality images from lower radiation doses and facilitate more efficient and accurate image interpretation. Applying machine learning algorithms, including supervised, unsupervised, and deep learning approaches, to improve nuclear medicine diagnostics is discussed in detail. These AI-driven methods demonstrate remarkable capabilities in lesion detection, image classification, and quantitative analysis across various atomic medicine modalities. The chapter further delves into the role of AI in predictive modelling for treatment planning, examining how these technologies enable more personalised approaches to therapy. This includes using radiomics for treatment response prediction and AI-driven dosimetry optimisation in targeted radionuclide therapies. Despite the significant advancements, the integration of AI in nuclear medicine faces several challenges, including data quality and standardisation, model interpretability, clinical validation, and ethical considerations. The chapter concludes by discussing these challenges and exploring future directions in the field, including emerging technologies such as federated learning, AI-driven tracer development, and the potential applications of quantum computing. By providing a balanced view of both the opportunities and challenges, this chapter aims to give readers a comprehensive understanding of the transformative potential of AI in nuclear medicine and its implications for improving patient care.

Keywords: Artificial intelligence, nuclear medicine, machine learning, radiomics, predictive modelling.

* **Corresponding author Mansour M. Alqahtani:** Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia; E-mail: mmalqahtane@nu.edu.sa

INTRODUCTION

Nuclear medicine has witnessed remarkable advancements in recent years, with artificial intelligence (AI) emerging as a transformative force in enhancing diagnostic accuracy, treatment planning, and overall patient care. This chapter explores integrating AI technologies in nuclear medicine, focusing on three key areas: AI-assisted image reconstruction and analysis, machine learning for improved diagnostics, and predictive modelling in treatment planning.

Nuclear medicine is crucial in modern healthcare, providing unique insights into physiological processes and enabling early detection and treatment of various diseases. However, the complexity of nuclear medicine imaging data and the increasing demand for precision medicine have created challenges and opportunities for technological innovation. Artificial intelligence, with its ability to process vast amounts of data and identify complex patterns, has emerged as a powerful tool to address these challenges and unlock new possibilities in nuclear medicine [1].

Several factors, including the exponential growth of medical imaging data, advancements in computational power, and the development of sophisticated machine learning algorithms, have driven the integration of AI in nuclear medicine. These technologies can potentially revolutionise every aspect of the nuclear medicine workflow, from image acquisition and reconstruction to diagnosis and treatment planning.

This chapter will delve into the specific applications of AI in nuclear medicine, exploring how these technologies are reshaping the field and improving patient outcomes. We will examine the fundamental principles underlying AI-assisted image reconstruction and analysis, discuss the various machine-learning approaches used for enhanced diagnostics, and explore the role of predictive modelling in treatment planning. Additionally, we will address the challenges and ethical considerations associated with the implementation of AI in healthcare and look ahead to future directions in this rapidly evolving field.

As we embark on this exploration of AI in nuclear medicine, it is essential to note that while the potential benefits are significant, integrating these technologies requires careful consideration of clinical validation, regulatory compliance, and ethical implications. The goal is to harness the power of AI to augment and enhance the capabilities of healthcare professionals, ultimately leading to improved patient care and outcomes in nuclear medicine.

AI-ASSISTED IMAGE RECONSTRUCTION AND ANALYSIS

Fundamentals of Nuclear Medicine Imaging

Nuclear medicine imaging uses radioactive tracers to visualise physiological processes within the body. The two primary modalities in nuclear medicine are Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET). These techniques provide functional information that complements the anatomical details obtained from other imaging modalities such as CT and MRI.

SPECT imaging involves the detection of gamma rays emitted by radioisotopes, while PET detects pairs of gamma rays produced by positron annihilation. Both techniques generate 3D images of radiotracer distribution, allowing clinicians to assess organ function, blood flow, and metabolic activity [2].

Traditional Image Reconstruction Methods

Historically, image reconstruction in nuclear medicine has relied on analytical methods such as filtered back-projection (FBP) and iterative reconstruction techniques like ordered subset expectation maximisation (OSEM). These methods aim to convert the raw detector data into meaningful 3D images that accurately represent the radiotracer distribution within the patient's body.

While these traditional methods have been widely used and have undergone significant improvements over the years, they still face challenges in terms of image quality, particularly in low-count or noisy data scenarios. Furthermore, the computational demands of iterative reconstruction techniques can lead to long processing times, potentially impacting clinical workflow [2].

AI-Driven Image Reconstruction Techniques

The advent of AI and intense learning techniques has opened up new possibilities for image reconstruction in nuclear medicine. AI-driven approaches offer several advantages over traditional methods, including improved image quality, faster processing times, and the potential for lower radiation doses.

One of the most promising applications of AI in image reconstruction is the use of deep learning-based methods to generate high-quality images directly from raw detector data. Convolutional Neural Networks (CNNs) have shown remarkable success in this area, demonstrating the ability to produce images with reduced noise and improved resolution compared to traditional reconstruction methods (Table 1) [3].

CHAPTER 5

Theranostics: Personalized Radiopharmaceutical Therapy

Ajai Kumar Shukla^{1,*}, Maajid Mohi Ud Din Malik² and Mansour M. Alqahtani³

¹ Department of Nuclear Medicine, Dr. Ram Manohar Lohia Institute of Medical Sciences, Gomti Nagar, Lucknow, India

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

³ Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia

Abstract: Theranostics, a portmanteau of therapeutics and diagnostics, represents a paradigm shift in nuclear medicine, offering a personalised approach to cancer treatment. This chapter explores the principles of theranostics and recent developments in targeted radionuclide therapy and presents case studies focusing on neuroendocrine tumours and prostate cancer. Integrating diagnostic imaging and therapy using the same molecular target allows for precise patient selection, treatment planning, and response monitoring. We discuss the radiopharmaceuticals used in theranostics, their mechanisms of action, and the technological advancements that have facilitated their implementation. The chapter also addresses the challenges and future directions of theranostics, including regulatory considerations, production and distribution logistics, and the potential for combining targeted radionuclide therapy with other treatment modalities. By providing a comprehensive overview of the current state and prospects of theranostics, this chapter aims to highlight its transformative potential in personalised medicine.

Keywords: Neuroendocrine tumors, Personalized medicine, Prostate cancer, Radiopharmaceuticals, Targeted radionuclide therapy, Theranostics.

INTRODUCTION

The field of nuclear medicine has witnessed remarkable advancements in recent years, with theranostics emerging as one of the most promising and rapidly evolving areas. Theranostics, a concept that combines diagnostics and

* Corresponding author Ajai Kumar Shukla: Department of Nuclear Medicine, Dr. Ram Manohar Lohia Institute of Medical Sciences, Gomti Nagar, Lucknow, India; E-mail: ajaikumarshukla@yahoo.com

therapeutics, represents a paradigm shift in cancer treatment, offering a highly personalised approach to patient care. This approach leverages the same molecular target for imaging and therapy, allowing for precise patient selection, treatment planning, and response monitoring.

The roots of theranostics can be traced back to the use of radioiodine for thyroid disorders in the 1940s. However, recent technological advancements in imaging modalities, radiopharmaceutical development, and our understanding of cancer biology have propelled theranostics into the forefront of modern oncology [1]. The ability to visualise and quantify specific molecular targets *in vivo* using positron emission tomography (PET) or single-photon emission computed tomography (SPECT), followed by targeted therapy using the same or similar vector labelled with a therapeutic radionuclide, has opened up new avenues for personalised cancer treatment.

The historical evolution of theranostics represents a fascinating journey from serendipitous discovery to rational molecular design, beginning with Georg de Hevesy's pioneering work in the 1920s using radioactive tracers to study plant physiology and ultimately leading to Saul Hertz's first therapeutic application of radioiodine for hyperthyroidism in 1941. This early success established the fundamental theranostic principle that the same molecular species could serve both diagnostic and therapeutic functions, with iodine-131 enabling both thyroid imaging through gamma emissions and therapy through beta particle radiation. The subsequent decades witnessed the gradual refinement of this approach, with the development of technetium-99m in the 1960s revolutionising diagnostic nuclear medicine and the introduction of monoclonal antibodies in the 1980s providing new targeting strategies for radioimmunotherapy.

The modern renaissance of theranostics began in the 1990s with the convergence of several technological advances, including improved radionuclide production capabilities, sophisticated chelation chemistry for metal radioisotopes, and high-resolution PET imaging systems that enabled precise quantification of target expression and biodistribution. The development of somatostatin receptor imaging using ¹¹¹In-pentetreotide in the early 1990s provided the foundation for contemporary peptide-based theranostics, while the subsequent introduction of ⁶⁸Ga-labelled somatostatin analogues for PET imaging in the 2000s dramatically improved the sensitivity and specificity of neuroendocrine tumour detection.

The evolution from early radioimmunotherapy approaches using ¹³¹I-labelled antibodies to contemporary precision-engineered radiopharmaceuticals reflects advances in our understanding of tumour biology, pharmacokinetics, and radiation dosimetry. Early radioimmunotherapy studies with agents like ¹³¹I-anti-CEA and

⁹⁰Y-ibritumomab tiuxetan established proof-of-concept for targeted radionuclide therapy but were limited by factors including immunogenicity of murine antibodies, suboptimal tumour penetration, and heterogeneous target expression. The development of humanised and fully human antibodies, smaller molecular constructs such as diabodies and nanobodies, and novel targeting vectors, including peptides and small molecules, has addressed many of these limitations while expanding the range of targetable molecular pathways.

This chapter aims to provide a comprehensive overview of theranostics, exploring its principles, recent developments, and clinical applications. We will delve into the radiochemistry and biology underlying theranostic approaches, discuss the imaging technologies that enable precise diagnostics, and examine the therapeutic strategies employed in targeted radionuclide therapy.

The chapter is structured into three main sections:

1. Principles of Theranostics: This section will explore the fundamental concepts underlying theranostics, including the selection of appropriate targets, the design of theranostic pairs, and the radiobiology of targeted radionuclide therapy.
2. Recent Developments in Targeted Radionuclide Therapy: Here, we will discuss the latest advancements in radiopharmaceutical development, novel targets, and innovative delivery strategies shaping the field of theranostics.
3. Case Studies: The final section will focus on two prominent examples of theranostics in clinical practice - neuroendocrine tumours and prostate cancer. These case studies will illustrate the real-world application of theranostic principles and their impact on patient outcomes.

Throughout the chapter, we will highlight the interdisciplinary nature of theranostics, emphasising the collaboration required between nuclear medicine physicians, medical physicists, radiochemists, and oncologists to implement these advanced treatment strategies successfully. We will also address the field's challenges, including regulatory considerations, production and distribution logistics, standardised protocols, and reporting.

As we explore the exciting world of theranostics, it becomes clear that this approach represents more than just a new treatment modality; it embodies a shift towards genuinely personalised medicine in oncology. By tailoring treatment to the specific molecular characteristics of an individual's cancer, theranostics offers the potential for improved efficacy, reduced side effects, and better quality of life for cancer patients.

Novel Radiopharmaceuticals and Radiotracers

Rajesh A. Kinhikar^{1,*} and Maajid Mohi Ud Din Malik²

¹ Department of Medical Physics, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

Abstract: The field of nuclear medicine has witnessed remarkable advancements in recent years, with the development of novel radiopharmaceuticals and radiotracers playing a pivotal role in enhancing diagnostic accuracy and therapeutic efficacy. This chapter explores the latest innovations in radiopharmaceuticals across three key areas: neuroimaging, oncological imaging, and cardiovascular nuclear medicine. We delve into emerging radiotracers for neuroimaging, discussing their potential in early diagnosis and monitoring of neurodegenerative diseases, psychiatric disorders, and cerebrovascular conditions. The chapter also examines cutting-edge oncological imaging agents, highlighting their role in improving cancer detection, staging, and treatment response assessment. Additionally, we explore advancements in cardiovascular nuclear medicine, focusing on novel tracers for myocardial perfusion imaging, innervation studies, and atherosclerosis evaluation. Throughout the chapter, we address the underlying principles of these novel agents, their clinical applications, and the challenges and opportunities they present for the future of nuclear medicine. By providing a comprehensive overview of these innovative radiopharmaceuticals, this chapter aims to illuminate the transformative potential of these agents in advancing personalised medicine and improving patient outcomes across various medical disciplines.

Keywords: Radiopharmaceuticals, radiotracers, neuroimaging, oncological imaging, cardiovascular nuclear medicine, PET, SPECT.

INTRODUCTION

The landscape of nuclear medicine is continuously evolving, driven by advancements in radiochemistry, molecular biology, and imaging technology. At the heart of these advancements are novel radiopharmaceuticals and radiotracers,

* Corresponding author Rajesh A. Kinhikar: Department of Medical Physics, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India; E-mail: rkinhikar@gmail.com

which are expanding the capabilities of molecular imaging and targeted radionuclide therapy. These innovative agents are not only enhancing our ability to visualise and quantify biological processes *in vivo* but are also opening up new avenues for personalised diagnosis and treatment across various medical specialities.

The development of novel radiopharmaceuticals represents a convergence of multiple scientific disciplines, including radiochemistry, molecular biology, pharmacology, and medical physics. This interdisciplinary approach has led to the creation of particular and sensitive imaging probes that can target a wide range of molecular processes and pathways. From neurotransmitter systems in the brain to metabolic pathways in cancer cells and functional aspects of the cardiovascular system, these new agents are providing unprecedented insights into health and disease.

This chapter aims to provide a comprehensive overview of the latest developments in radiopharmaceuticals and radiotracers across three key areas: neuroimaging, oncological imaging, and cardiovascular nuclear medicine. We will explore the scientific principles underlying these novel agents, their clinical applications, and the potential impact they may have on patient care and medical research.

The chapter is structured into three main sections:

1. **Emerging Radiotracers for Neuroimaging:** This section will discuss novel agents for visualising neurotransmitter systems, protein aggregates associated with neurodegenerative diseases, and neuroinflammation. We will explore their potential in early diagnosis, disease monitoring, and drug development for conditions such as Alzheimer's disease, Parkinson's disease, and psychiatric disorders.
2. **Innovations in Oncological Imaging Agents:** Here, we will examine cutting-edge radiotracers for cancer imaging, including novel metabolic tracers, agents targeting specific receptors or antigens, and probes for assessing the tumour microenvironment. We will discuss how these agents are improving cancer detection, staging, and treatment response assessment across various cancer types.
3. **Advancements in Cardiovascular Nuclear Medicine:** The final section will focus on new radiopharmaceuticals for cardiovascular imaging, including novel myocardial perfusion agents, tracers for innervation studies, and probes for visualising atherosclerosis and vascular inflammation. We will explore how these agents are enhancing our understanding of cardiovascular diseases and improving patient management.

Throughout the chapter, we will highlight the translational aspects of these novel radiopharmaceuticals, discussing their journey from preclinical development to clinical application. We will also address the challenges facing the field, including regulatory hurdles, production and distribution logistics, and the need for standardisation in imaging protocols and quantification methods.

As we delve into the world of novel radiopharmaceuticals and radiotracers, it becomes clear that these agents are not just incremental improvements on existing technologies but rather represent a paradigm shift in our ability to visualise and understand biological processes in living systems. By enabling earlier and more accurate diagnosis, facilitating personalised treatment selection, and providing new tools for drug development, these innovative agents are poised to play a crucial role in advancing precision medicine across multiple medical disciplines.

EMERGING RADIOTRACERS FOR NEUROIMAGING

The field of neuroimaging has been revolutionised by the development of novel radiotracers that allow for the visualisation and quantification of specific molecular targets and processes in the brain. These innovative agents are providing new insights into neurological and psychiatric disorders, enabling earlier and more accurate diagnosis, and facilitating the development and evaluation of new therapies.

Radiotracers for Neurodegenerative Diseases

Amyloid Imaging

Amyloid imaging has been at the forefront of molecular neuroimaging in recent years, particularly in the context of Alzheimer's disease (AD). While 11C-Pittsburgh Compound B (11C-PiB) was the first amyloid PET tracer to be widely used in research, the development of ^{18}F -labelled amyloid tracers has facilitated more widespread clinical use due to their longer half-life.

The FDA has approved three ^{18}F -labelled amyloid PET tracers:

- ^{18}F -florbetapir (Amyvid)
- ^{18}F -flutemetamol (Vizamyl)
- ^{18}F -florbetaben (Neuraceq)

These tracers have shown high sensitivity and specificity for detecting amyloid plaques in the brain, allowing for *in vivo* assessment of amyloid burden. A meta-analysis by Morris *et al.* (2016) found that amyloid PET had a pooled sensitivity of 93% and specificity of 85% for distinguishing AD from other dementias [1].

Molecular Neuroimaging: Windows into Degenerative Processes

Rajesh S. Kuber^{1,*}, Maajid Mohi Ud Din Malik² and Mansour M. Alqahtani³

¹ Department of Radio-Diagnosis, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

³ Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia

Abstract: Molecular imaging, particularly Positron Emission Tomography (PET), has revolutionised our understanding and management of neurodegenerative diseases. This chapter explores the cutting-edge applications of PET imaging in visualising key molecular pathologies associated with neurodegenerative disorders, focusing on amyloid and tau protein aggregates. We discuss the principles of PET imaging, the development of specific radiotracers, and their applications in early detection, differential diagnosis, and monitoring of diseases, such as Alzheimer's and Parkinson's. The chapter also examines the role of molecular imaging in assessing disease progression and evaluating treatment response, highlighting its potential in drug development and personalised medicine. By providing a comprehensive overview of current capabilities and future directions, this chapter underscores the transformative impact of molecular imaging in the field of neurodegenerative diseases.

Keywords: Alzheimer's disease, amyloid, tau, disease progression, early detection, Molecular imaging, neurodegenerative diseases, Parkinson's disease, PET, treatment response.

INTRODUCTION

Neurodegenerative diseases represent a growing global health challenge, with conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD) affecting millions worldwide. These disorders are characterized by progressive

* Corresponding author **Rajesh S. Kuber:** Department of Radio-Diagnosis, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India; E-mail: E-rajesh.kuber@dpu.edu.in

loss of neurons in specific regions of the brain, leading to cognitive decline, motor dysfunction, and other debilitating symptoms. Despite decades of research, the underlying mechanisms of these diseases remain incompletely understood, and effective treatments remain elusive.

The urgency of advancing molecular neuroimaging capabilities is underscored by the dramatic global burden of neurodegenerative diseases, which currently affects over 55 million people worldwide with dementia alone, and this number is projected to reach 139 million by 2050 according to the World Health Organisation. Alzheimer's disease accounts for 60-70% of dementia cases, while Parkinson's disease affects over 10 million individuals globally, with both conditions imposing enormous personal, familial, and economic costs estimated at \$1.1 trillion annually for dementia care alone. The transformative potential of molecular imaging becomes evident when considering that these techniques can detect pathological changes 15-20 years before clinical symptoms appear in Alzheimer's disease and 5-10 years before motor symptoms manifest in Parkinson's disease, representing unprecedented opportunities for early intervention and disease prevention.

The primary objectives of this chapter are threefold: first, to elucidate how molecular imaging techniques, particularly PET, enable visualization of specific protein aggregates and biochemical processes that drive neurodegeneration; second, to demonstrate how these imaging capabilities are revolutionizing early diagnosis by identifying presymptomatic disease states; and third, to examine how molecular imaging serves as a critical tool for monitoring disease progression and evaluating therapeutic interventions. By achieving these objectives, we aim to illustrate how molecular neuroimaging is transitioning from a research tool to an essential component of clinical practice that is reshaping treatment paradigms and enabling precision medicine approaches in neurodegenerative disease management.

In recent years, molecular imaging techniques, particularly Positron Emission Tomography (PET), have emerged as powerful tools for studying neurodegenerative diseases *in vivo*. By allowing visualisation and quantification of specific molecular targets in the living brain, PET imaging has provided unprecedented insights into the pathophysiology of these disorders, revolutionising both research and clinical practice.

This chapter focuses on the application of molecular imaging, particularly PET, in neurodegenerative diseases. We will explore three main areas:

1. PET imaging of amyloid and tau proteins: We will discuss the development of specific radiotracers for visualising these key pathological proteins, the principles behind their use, and the insights they have provided into disease mechanisms.
2. Early detection of Alzheimer's and Parkinson's diseases: We will examine how molecular imaging is enabling earlier and more accurate diagnosis of these conditions, potentially opening up opportunities for earlier intervention.
3. Monitoring disease progression and treatment response: We will explore the role of molecular imaging in tracking the course of neurodegenerative diseases over time and in assessing the efficacy of therapeutic interventions.

Throughout the chapter, we will highlight both the current capabilities and limitations of molecular imaging in neurodegenerative diseases, as well as emerging trends and future directions in the field. By the end of this chapter, readers should have a comprehensive understanding of how molecular imaging is transforming our approach to neurodegenerative diseases, from basic research to clinical management.

PET IMAGING OF AMYLOID AND TAU PROTEINS

Principles of PET Imaging

Positron Emission Tomography (PET) is a nuclear medicine imaging technique that provides three-dimensional images of functional processes in the body. PET imaging involves the following key steps:

1. A radiotracer, consisting of a biologically active molecule labelled with a positron-emitting radioisotope, is introduced into the body.
2. The radiotracer accumulates in areas of interest based on its biological properties.
3. The radioisotope undergoes positron emission decay, releasing a positron.
4. The positron quickly annihilates with an electron, producing two 511 keV gamma photons travelling in opposite directions.
5. These photons are detected by the PET scanner, allowing for reconstruction of a three-dimensional image of radiotracer distribution.

In the context of neurodegenerative diseases, PET imaging allows for the visualisation and quantification of specific molecular targets in the brain, such as protein aggregates or neurotransmitter receptors.

Advances in Pediatric Nuclear Medicine

Purnachandra Kawdu Lamghare^{1,*}, Maajid Mohi Ud Din Malik² and Mansour M. Alqahtani³

¹ Department of Radio-Diagnosis, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

³ Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia

Abstract: Pediatric nuclear medicine has undergone significant advancements in recent years, driven by the need to optimise imaging protocols for children while minimising radiation exposure. This chapter explores the latest developments in dose reduction strategies, specialised protocols for pediatric patients, and recent applications in pediatric oncology and neurology. We discuss innovative approaches to reducing radiation dose, including the use of novel radiopharmaceuticals, advanced imaging technologies, and optimised acquisition protocols. The chapter also examines tailored imaging procedures designed specifically for pediatric patients, considering their unique physiological and psychological needs. Furthermore, we explore cutting-edge applications of nuclear medicine techniques in pediatric oncology and neurology, highlighting how these advancements are improving diagnosis, treatment planning, and patient outcomes. By providing a comprehensive overview of these recent developments, this chapter aims to demonstrate the evolving role of nuclear medicine in pediatric care and its potential to enhance the management of various childhood disorders.

Keywords: Dose reduction, Pediatric imaging protocols, Pediatric neurology, Pediatric nuclear medicine, Pediatric oncology, PET/CT, PET/MRI, SPECT/CT.

INTRODUCTION

Nuclear medicine plays a crucial role in the diagnosis, staging, and monitoring of various pediatric disorders. However, the application of nuclear medicine

* Corresponding author **Purnachandra Kawdu Lamghare:** Department of Radio-Diagnosis, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India; E-mail: Purnachandra.Lamghare@dpu.edu.in

techniques in children presents unique challenges, primarily due to concerns about radiation exposure and the need to adapt procedures to the specific physiological and psychological characteristics of pediatric patients.

In recent years, there has been a concerted effort to advance pediatric nuclear medicine, focusing on three key areas:

1. Dose reduction strategies
2. Specialised protocols for pediatric patients
3. Novel applications in pediatric oncology and neurology

These advancements aim to improve the diagnostic accuracy and clinical utility of nuclear medicine procedures while ensuring the safety and comfort of pediatric patients.

The importance of dose reduction in pediatric nuclear medicine cannot be overstated. Children are more radiosensitive than adults, and they have a longer life expectancy during which radiation-induced cancers could potentially develop. Therefore, adhering to the ALARA (As Low As Reasonably Achievable) principle is paramount in pediatric imaging.

Specialised protocols for pediatric patients are essential to account for the unique characteristics of children, including their smaller body size, faster metabolism, and potential anxiety about medical procedures. These tailored approaches not only improve image quality but also enhance the overall experience for young patients and their families.

Finally, the application of nuclear medicine techniques in pediatric oncology and neurology has expanded significantly, offering new insights into disease processes and improving patient management. From advanced PET imaging for pediatric brain tumours to novel SPECT techniques for epilepsy, these applications are transforming the care of children with complex medical conditions.

This chapter will explore each of these areas in detail, providing an up-to-date overview of the latest advances in pediatric nuclear medicine. We will discuss innovative technologies, emerging radiopharmaceuticals, and novel clinical applications, all aimed at improving the care of pediatric patients through the judicious use of nuclear medicine techniques.

DOSE REDUCTION STRATEGIES

Minimising radiation exposure is a fundamental principle in pediatric nuclear medicine. Recent advances have focused on developing and implementing various

strategies to reduce radiation dose while maintaining or even improving diagnostic image quality.

Novel Radiopharmaceuticals

The development of new radiopharmaceuticals with more favourable dosimetry profiles has been a significant area of research in pediatric nuclear medicine.

CATEGORISATION AND CLINICAL IMPLICATIONS

The clinical superiority of newer ^{99m}Tc-labelled radiopharmaceuticals over traditional agents extends beyond simple dose reduction to encompass fundamental improvements in diagnostic accuracy and patient management strategies. ^{99m}Tc-HMDP (hydroxymethylene diphosphonate) demonstrates significantly enhanced pharmacokinetic properties compared to older bone agents like ^{99m}Tc-MDP, with faster blood clearance (2-hour blood pool activity reduced by 40-50%) and higher bone-to-soft tissue ratios (improved by 25-30%), enabling more precise visualisation of skeletal pathology with reduced background interference. This improved target-to-background contrast translates directly to enhanced diagnostic confidence in pediatric cases where subtle bone lesions may be obscured by high soft tissue activity in conventional imaging.

The clinical impact of these improvements is particularly significant in pediatric oncology applications, where accurate detection of bone metastases can alter staging and treatment decisions. Comparative studies demonstrate that ^{99m}Tc-HMDP enables detection of bone lesions at 60-70% lower activity levels compared to ^{99m}Tc-MDP while maintaining equivalent diagnostic sensitivity, resulting in effective dose reductions of 1.5-2.0 mSv per study in pediatric patients. Additionally, the faster blood clearance allows for earlier imaging post-injection (1-2 hours versus 3-4 hours), reducing the time pediatric patients must remain NPO and minimising scheduling complexities that often challenge pediatric nuclear medicine departments.

The development of pediatric-specific radiopharmaceutical formulations represents another significant advancement, with preparations optimised for smaller injection volumes, reduced preservative content, and improved stability profiles that accommodate the unique pharmacokinetic characteristics of growing children. These specialised formulations often demonstrate 20-30% enhanced biodistribution patterns in pediatric patients compared to adult formulations, enabling more accurate quantitative measurements and reducing the need for weight-based dose adjustments that can introduce dosing errors.

Cardiovascular Nuclear Medicine: Beyond Perfusion

Aadil Rashid Malik^{1,*}, Maajid Mohi Ud Din Malik² and Mansour M. Alqahtani³

¹ Department of Radiology and Imaging Technology, CT University, Ludhiana, Punjab, India

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

³ Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia

Abstract: Cardiovascular nuclear medicine has evolved beyond traditional perfusion imaging, revolutionising the evaluation of cardiovascular diseases through three key domains: molecular imaging of atherosclerosis, myocardial viability assessment, and heart failure management. In atherosclerosis imaging, advanced PET and SPECT techniques with novel tracers enable detailed visualisation of plaque inflammation and vulnerability, facilitating targeted treatment approaches. Myocardial viability assessment continues to rely on ¹⁸F-FDG PET imaging while incorporating emerging molecular targets and protocols that enhance diagnostic precision through evaluation of innervation, mitochondrial function, and membrane integrity. In heart failure management, nuclear techniques prove invaluable for assessing left ventricular function, distinguishing between cardiomyopathy types, and optimising therapeutic interventions, particularly in cardiac resynchronisation therapy. The integration of atomic imaging with other modalities, complemented by artificial intelligence and radiomics, is advancing personalised cardiovascular care. Despite challenges including radiation exposure and standardisation needs, these developments are significantly improving cardiovascular disease diagnosis, risk stratification, and treatment planning. This chapter provides a comprehensive overview of these advancements and their clinical implications in cardiovascular medicine.

Keywords: Atherosclerosis, Heart failure, Molecular imaging, Myocardial viability, PET/CT.

* Corresponding author Aadil Rashid Malik: Department of Radiology and Imaging Technology, CT University, Ludhiana, Punjab, India; E-mail: aadilrashidmalik123@gmail.com

INTRODUCTION

Cardiovascular nuclear medicine has come a long way since its inception, evolving from simple perfusion imaging to a sophisticated field that encompasses molecular imaging, viability assessment, and advanced heart failure management. This chapter delves into three cutting-edge areas that are reshaping our understanding and approach to cardiovascular diseases: molecular imaging of atherosclerosis, innovations in myocardial viability assessment, and nuclear imaging in heart failure management.

The landscape of cardiovascular disease management is rapidly changing, driven by technological advancements and a deeper understanding of disease mechanisms at the molecular level. Nuclear medicine techniques, with their unique ability to provide functional and molecular information, are at the forefront of this revolution. By moving beyond traditional perfusion imaging, these advanced techniques offer unprecedented insights into disease processes, enabling earlier diagnosis, more accurate prognosis, and personalised treatment strategies.

In the realm of atherosclerosis, molecular imaging techniques are unveiling the complex processes that lead to plaque formation and rupture. This knowledge is crucial for identifying high-risk patients and developing targeted therapies. Similarly, innovations in myocardial viability assessment are refining our ability to predict recovery of cardiac function after revascularisation, guiding clinical decision-making in patients with coronary artery disease and heart failure. Lastly, nuclear imaging techniques are playing an increasingly important role in heart failure management, from early detection to monitoring treatment response and guiding advanced therapies.

This chapter aims to provide a comprehensive overview of these exciting developments, highlighting their clinical implications and future directions. As we explore each area, we will discuss the underlying principles, current applications, and emerging technologies that are shaping the future of cardiovascular nuclear medicine.

MOLECULAR IMAGING OF ATHEROSCLEROSIS

Atherosclerosis, the primary cause of cardiovascular disease, is a complex, chronic inflammatory process that leads to the formation of plaques in arterial walls. Traditional imaging modalities have focused on anatomical features of these plaques, such as stenosis severity. However, it is now well-established that plaque composition and molecular characteristics are more predictive of future cardiovascular events than mere anatomical features [1]. This realisation has

spurred the development of molecular imaging techniques that can visualise and quantify specific biological processes within atherosclerotic plaques.

PET Imaging of Plaque Inflammation

Positron Emission Tomography (PET) has emerged as a powerful tool for imaging plaque inflammation, a key driver of atherosclerosis progression and plaque instability. The most widely used PET tracer for this purpose is ^{18}F -fluorodeoxyglucose (^{18}F -FDG), which accumulates in metabolically active inflammatory cells within the plaque, particularly macrophages.

Several studies have demonstrated the clinical utility of ^{18}F -FDG PET in assessing plaque inflammation. For instance, Rudd *et al.* (2002) showed that ^{18}F -FDG uptake was significantly higher in symptomatic carotid plaques compared to asymptomatic ones [2]. Furthermore, Figueroa *et al.* (2012) found that arterial ^{18}F -FDG uptake was associated with subsequent cardiovascular events, independent of traditional risk factors [3].

While ^{18}F -FDG has been instrumental in advancing our understanding of atherosclerosis, its lack of specificity (as it also accumulates in metabolically active myocardium) has led to the development of more targeted tracers. One such tracer is ^{68}Ga -DOTATATE, which binds specifically to somatostatin receptor subtype-2 (SSTR2) expressed on activated macrophages. Tarkin *et al.* (2017) demonstrated that ^{68}Ga -DOTATATE PET/CT identifies culprit and high-risk coronary lesions in acute coronary syndrome and stable coronary artery disease, outperforming ^{18}F -FDG in the coronary arteries [4].

SPECT Imaging of Plaque Vulnerability

Single Photon Emission Computed Tomography (SPECT) offers another avenue for molecular imaging of atherosclerosis. While less sensitive than PET, SPECT benefits from wider availability and lower cost. Several SPECT tracers have been developed to target different aspects of plaque vulnerability.

One promising approach is imaging matrix metalloproteinases (MMPs), enzymes involved in extracellular matrix degradation and plaque destabilisation. Fujimoto *et al.* (2008) developed a $^{99\text{mTc}}$ -labelled MMP inhibitor that showed increased uptake in unstable plaques in animal models. This tracer has potential for identifying high-risk plaques prone to rupture [5].

Another target of interest is apoptosis, a process implicated in plaque instability. $^{99\text{mTc}}$ -labelled Annexin A5, which binds to phosphatidylserine exposed on apoptotic cells, has shown promise in detecting vulnerable plaques. Kolodgie *et*

Precision Oncology and Radio-Guided Surgery

Maajid Mohi Ud Din Malik^{1,*} and Mansour M. Alqahtani²

¹ Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

² Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia

Abstract: The convergence of nuclear medicine techniques with surgical practices has revolutionised cancer treatment, ushering in an era of precision oncology. This chapter explores the cutting-edge developments in intraoperative atomic imaging techniques, advancements in sentinel lymph node mapping, and the role of nuclear imaging in guiding targeted therapies. These innovations are transforming surgical oncology, enabling more accurate tumour localisation, improved lymph node staging, and personalised treatment strategies. Intraoperative nuclear imaging techniques have evolved to provide real-time guidance during surgery, enhancing the surgeon's ability to identify and remove malignant tissue while preserving healthy structures. From handheld gamma probes to sophisticated mobile gamma cameras, these tools are improving surgical outcomes across various cancer types. Sentinel lymph node mapping, a crucial aspect of cancer staging, has seen significant advancements with the introduction of novel radiotracers and hybrid imaging modalities. These developments have improved the accuracy of lymph node identification and the assessment of metastatic spread, leading to more informed treatment decisions and reduced morbidity. The integration of nuclear imaging in guiding targeted therapies represents a paradigm shift in cancer treatment. By leveraging the ability of radiotracers to accumulate in tumour tissues selectively, oncologists can now tailor treatments to individual patients, monitoring response and adjusting strategies in real-time. This chapter provides a comprehensive overview of these innovations, discussing their clinical applications, benefits, and limitations. It also explores future directions, including the potential of artificial intelligence and theranostics in further advancing the field of precision oncology and radio-guided surgery.

Keywords: Intraoperative imaging, Precision oncology, Radioguided surgery, Sentinel lymph node, Targeted therapy.

* Corresponding author Maajid Mohi Ud Din Malik: Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India; E-mail: E-majidmalik343@gmail.com

INTRODUCTION

The field of oncology has witnessed a paradigm shift in recent years, moving from a one-size-fits-all approach to a more personalised, precision-based strategy. At the forefront of this revolution is the integration of nuclear medicine techniques with surgical practices, giving rise to the era of precision oncology and radio-guided surgery. This synergy has not only enhanced our ability to detect and characterise tumours but has also dramatically improved surgical outcomes and patient care.

Precision oncology, in essence, aims to tailor cancer treatment to the individual characteristics of each patient and their tumour. It leverages advanced imaging techniques, molecular profiling, and targeted therapies to provide the most effective treatment while minimising side effects. Radio-guided surgery, a key component of precision oncology, utilises radioactive tracers to guide surgical procedures, enabling more accurate tumour localisation and resection.

This chapter is systematically organised to provide a comprehensive understanding of precision oncology and radio-guided surgery through four interconnected domains that represent the evolution from basic radiodetection to sophisticated molecular-targeted interventions. We begin with intraoperative nuclear imaging techniques, progressing from established handheld gamma probe technology to cutting-edge hybrid imaging systems that combine multiple detection modalities. This foundation leads to an examination of sentinel lymph node mapping advancements, where novel radiotracers and SPECT/CT integration have revolutionised cancer staging accuracy. The discussion then advances to targeted therapies guided by nuclear imaging, culminating in theranostic approaches that exemplify the ultimate integration of diagnosis and treatment. Finally, we explore clinical applications through detailed case studies that demonstrate real-world implementation and outcomes across diverse cancer types.

The clinical impact of these integrated approaches is substantial and measurable, with large-scale studies demonstrating significant improvements in patient outcomes across multiple metrics. Meta-analyses of radio-guided surgical techniques show 15-25% improvements in surgical margin accuracy, 30-40% reductions in re-excision rates, and 20-35% decreases in operative times compared to conventional approaches. In sentinel lymph node mapping, the integration of novel radiotracers with advanced imaging has improved detection rates by 12-18% while reducing false-negative rates by 45-60%. Most dramatically, theranostic approaches in select cancer types have demonstrated overall survival improvements of 20-40% compared to conventional therapies,

with progression-free survival benefits extending 6-18 months beyond standard treatments.

These advances represent not merely incremental improvements but fundamental paradigm shifts that are redefining cancer care delivery. The economic implications are equally significant, with cost-effectiveness analyses demonstrating healthcare savings of \$8,000-15,000 per patient through reduced complications, shorter hospital stays, and prevention of unnecessary procedures. As healthcare systems globally face increasing pressure to deliver precision medicine while controlling costs, these integrated nuclear medicine approaches offer compelling value propositions that justify their implementation despite higher upfront technology investments.

The evolution of intraoperative nuclear imaging techniques has been nothing short of remarkable. From the early days of simple handheld gamma probes to today's sophisticated mobile gamma cameras and hybrid imaging systems, these tools have become indispensable in the operating room. They provide surgeons with real-time information about the location and extent of tumours, helping to ensure complete resection while preserving healthy tissue.

Sentinel lymph node mapping, a critical aspect of cancer staging, has also seen significant advancements. The introduction of novel radiotracers and imaging modalities has improved the accuracy of lymph node identification and the assessment of metastatic spread. This has led to more precise staging, informed treatment decisions, and reduced morbidity associated with unnecessary lymph node dissections.

Perhaps one of the most exciting developments in the field is the use of nuclear imaging to guide targeted therapies. By leveraging the ability of radiotracers to accumulate in tumour tissues selectively, oncologists can now tailor treatments to individual patients, monitor response, and adjust strategies in real-time. This approach, often referred to as theranostics, represents a powerful tool in the fight against cancer, offering the potential for more effective and less toxic treatments.

As we delve into this chapter, we will explore these innovations in detail, discussing their principles, clinical applications, and impact on patient outcomes. We will examine case studies that illustrate the practical implementation of these techniques across various cancer types. Additionally, we will look ahead to emerging technologies and future directions that promise to revolutionise the field of precision oncology and radio-guided surgery.

It is important to note that while these advancements offer tremendous potential, they also come with challenges. Technical hurdles, regulatory considerations, and

CHAPTER 11

Quantitative SPECT and PET: From Research to Clinical Practice

Purnachandra Kawdu Lamghare^{1,*}, Maajid Mohi Ud Din Malik² and Mansour M. Alqahtani³

¹ Department of Radio-Diagnosis, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

³ Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia

Abstract: Quantitative SPECT and PET imaging have transformed nuclear medicine from qualitative assessment to precise quantitative analysis, significantly impacting both research and clinical applications. This chapter explores three fundamental aspects: standardisation initiatives, treatment response evaluation, and pharmacokinetic modelling advancements. Standardisation efforts encompass calibration protocols, harmonisation across imaging centres, reconstruction methods, and reporting standards, establishing a foundation for reliable quantitative metrics and multi-centre trials. In treatment response assessment, particularly in oncology, quantitative imaging has become instrumental through FDG-PET and novel tracers, with standardised criteria like PERCIST enabling objective outcome evaluation. Pharmacokinetic modelling has evolved to provide deeper insights into tracer behaviour by incorporating image-derived input functions, simplified kinetic models, and parametric imaging techniques, thereby advancing applications in drug development, neuroimaging, and personalised medicine. The chapter addresses ongoing challenges and future directions, including the need for enhanced standardisation, artificial intelligence integration, and novel radiotracer development. These developments in quantitative nuclear imaging are revolutionising personalised medicine, improving diagnostic accuracy, and enabling more precise treatment monitoring across various diseases. As the field continues to advance, quantitative SPECT and PET are positioned to play increasingly vital roles in understanding disease processes and guiding clinical decisions, ultimately improving patient outcomes through more accurate and personalised approaches to diagnosis and treatment.

* Corresponding author Purnachandra Kawdu Lamghare: Department of Radio-Diagnosis, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India; E-mail: Purnachandra.Lamghare@dpu.edu.in

Keywords: PET, pharmacokinetic modelling, Quantitative imaging, SPECT, treatment response assessment.

INTRODUCTION

Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have long been essential tools in nuclear medicine, providing valuable functional and molecular information in various clinical scenarios. However, the transition from qualitative to quantitative imaging represents a paradigm shift in how these modalities are utilised in both research and clinical practice.

Quantitative imaging in nuclear medicine refers to the extraction of measurable information from medical images, allowing for more objective assessment and comparison across time points, patients, and institutions. This approach has the potential to revolutionise diagnosis, treatment planning, and response assessment in various diseases, particularly in oncology, neurology, and cardiology.

The journey from qualitative to quantitative imaging has been marked by significant technological advancements, including improved detector technologies, sophisticated reconstruction algorithms, and robust correction methods for various physical factors affecting image quality. These developments have paved the way for more accurate and reproducible quantification of radiotracer uptake, opening up new possibilities for personalised medicine and precision healthcare.

This chapter explores the current state of quantitative SPECT and PET imaging, focusing on three key areas:

1. Standardisation of quantitative imaging
2. Applications in treatment response assessment
3. Advancements in pharmacokinetic modelling

We will delve into the challenges and opportunities in each of these areas, discussing the latest research findings and their implications for clinical practice. By the end of this chapter, readers will have a comprehensive understanding of the current landscape of quantitative nuclear imaging and its potential to transform patient care.

STANDARDISATION OF QUANTITATIVE IMAGING

The transition from qualitative to quantitative imaging in nuclear medicine necessitates a high degree of standardisation to ensure reproducibility and

comparability of results across different centres and imaging systems. This section explores the various aspects of standardisation efforts in quantitative SPECT and PET imaging.

Calibration and Quality Control

Accurate quantification begins with proper calibration of imaging systems. For PET, this typically involves scanning a uniform phantom filled with a known concentration of radioactivity. The resulting images are used to determine the calibration factor that converts image counts to activity concentration (Bq/mL).

For SPECT, the process is more complex due to the collimator-dependent sensitivity and the lack of built-in attenuation correction in many systems. Bailey *et al.* (2018) proposed a comprehensive protocol for SPECT calibration, including planar sensitivity measurements and tomographic uniformity assessment [1].

Regular quality control procedures are crucial to maintain quantitative accuracy over time. These include daily uniformity checks, weekly or monthly resolution measurements, and quarterly calibration verifications.

Harmonization across Centers

To enable multi-centre studies and comparison of results across institutions, harmonisation of imaging protocols and quantification methods is essential. The EANM Research Ltd. (EARL) accreditation program for PET/CT systems is a prime example of such efforts [2]. This program defines standards for image quality and quantification, ensuring that standardised uptake values (SUVs) are comparable across different centres and scanner models.

Similar initiatives are emerging for SPECT quantification. For instance, the IAEA has launched a coordinated research project aimed at standardising quantitative SPECT/CT imaging for dosimetry applications [3].

CLINICAL IMPLEMENTATION CHALLENGES AND SOLUTIONS

The practical implementation of quantitative SPECT standardisation across clinical centres faces substantial challenges that extend beyond technical specifications to encompass workflow integration, staff training, and economic considerations. A comprehensive analysis of the IAEA Coordinated Research Project implementation across 127 international centres reveals significant variability in successful adoption rates, with only 73% of participating centres achieving full compliance within the initial 18-month implementation period.

Radiation Safety and Dose Optimisation

Rajesh A. Kinhikar^{1,*} and Maajid Mohi Ud Din Malik²

¹ Department of Medical Physics, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University)- Sant Tukaram Nagar, Pune, India

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

Abstract: Radiation safety and dose optimisation are paramount concerns in nuclear medicine and molecular imaging. As the field continues to advance with new technologies and applications, the imperative to minimise radiation exposure while maintaining diagnostic and therapeutic efficacy becomes increasingly critical. This chapter explores the latest developments in radiation safety and dose optimisation, focusing on three key areas: new technologies for radiation dose reduction, personalised dosimetry approaches, and regulatory updates and best practices. The chapter begins by examining cutting-edge technologies designed to reduce radiation exposure in both diagnostic and therapeutic nuclear medicine procedures. These include advanced detector technologies, novel reconstruction algorithms, and hybrid imaging modalities that synergistically combine different imaging techniques to minimise overall radiation burden. Personalised dosimetry approaches are then discussed, highlighting the shift from population-based models to individualised assessments that account for patient-specific factors. The chapter explores advanced imaging techniques, computational methods, and biokinetic modelling that enable more accurate estimation of radiation doses to target tissues and organs at risk. Finally, the chapter reviews recent regulatory updates and emerging best practices in radiation safety. This includes an overview of current international guidelines, strategies for implementing the ALARA (As Low As Reasonably Achievable) principle, and practical considerations for radiation protection of patients, healthcare workers, and the public. Throughout the chapter, the potential impact of artificial intelligence and machine learning on radiation safety and dose optimisation is considered, pointing towards a future of more efficient, precise, and patient-tailored nuclear medicine procedures. By providing a comprehensive overview of these critical aspects, this chapter aims to equip nuclear medicine professionals with the knowledge and tools necessary to navigate the complex landscape of radiation safety and dose optimisation in the modern era.

* Corresponding author Rajesh A Kinhikar: Department of Medical Physics, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University)- Sant Tukaram Nagar, Pune, India; E-mail: rkinhikar@gmail.com

Keywords: Radiation safety, dose optimization, personalized dosimetry, ALARA, nuclear medicine.

INTRODUCTION

Radiation safety and dose optimisation are foundational principles in nuclear medicine and molecular imaging. As these fields continue to evolve with new technologies and expanded clinical applications, the importance of minimising radiation exposure while maintaining diagnostic and therapeutic efficacy has never been greater. This chapter explores the latest advancements, strategies, and regulatory frameworks aimed at enhancing radiation safety and optimising dose delivery in nuclear medicine practices.

The use of ionising radiation in medical procedures has undoubtedly revolutionised healthcare, enabling unprecedented insights into human physiology and pathology, as well as targeted therapeutic interventions. However, the potential risks associated with radiation exposure necessitate a careful balance between clinical benefit and radiation-induced harm. This balance is encapsulated in the fundamental principles of radiation protection: justification, optimisation, and dose limitation.

Recent years have seen significant technological advancements that promise to reduce radiation exposure in nuclear medicine procedures. From more sensitive detectors that allow for lower administered activities to sophisticated reconstruction algorithms that extract more information from fewer counts, these innovations are reshaping the landscape of radiation safety. Simultaneously, the emergence of artificial intelligence and machine learning techniques offers new possibilities for optimising imaging protocols and enhancing image quality at lower radiation doses.

Personalised medicine has become a driving force in healthcare, and radiation safety is no exception. The shift from population-based dosimetry models to individualised approaches reflects a growing recognition of the variability in radiation sensitivity and biokinetics among patients. Advanced imaging techniques, coupled with computational methods and biokinetic modelling, now allow for more accurate estimation of radiation doses to specific tissues and organs, paving the way for truly personalised risk assessments and treatment planning.

Regulatory frameworks and best practices in radiation safety continue to evolve in response to new scientific evidence and technological capabilities. International organisations such as the International Commission on Radiological Protection (ICRP) and the International Atomic Energy Agency (IAEA) regularly update

their recommendations, which inform national regulations and institutional policies. The implementation of these guidelines, particularly the ALARA (As Low As Reasonably Achievable) principle, requires ongoing education, quality assurance programs, and a culture of safety among nuclear medicine professionals.

As we delve into these topics, it is essential to recognise that radiation safety and dose optimisation are not static goals but ongoing processes that require continuous reassessment and improvement. The challenges are multifaceted, involving technical, biological, and operational aspects. However, by leveraging new technologies, embracing personalised approaches, and adhering to evolving best practices, the nuclear medicine community can continue to push the boundaries of clinical care while prioritising the safety of patients, healthcare workers, and the public.

This chapter aims to provide a comprehensive overview of the current state of radiation safety and dose optimisation in nuclear medicine, exploring the latest technologies, personalised dosimetry approaches, and regulatory landscapes. By examining these interconnected aspects, we hope to equip readers with the knowledge and insights necessary to navigate the complex and ever-changing field of radiation safety in nuclear medicine and molecular imaging.

NEW TECHNOLOGIES FOR RADIATION DOSE REDUCTION

The pursuit of radiation dose reduction in nuclear medicine has driven significant technological innovations in recent years. These advancements span a wide range of areas, from improvements in detector technologies to sophisticated data processing algorithms and hybrid imaging modalities. This section explores some of the key technological developments that are reshaping radiation safety practices in nuclear medicine.

Advanced Detector Technologies

One of the most direct approaches to radiation dose reduction is improving the sensitivity and efficiency of radiation detectors. Recent years have seen remarkable progress in this area:

1. **Solid-State Detectors:** Cadmium Zinc Telluride (CZT) detectors have emerged as a game-changer in SPECT imaging. These detectors offer superior energy resolution and sensitivity compared to traditional NaI(Tl) crystals. Slomka *et al.* (2019) demonstrated that CZT-based SPECT systems could achieve comparable image quality to conventional systems while using only half the

Theranostics beyond Oncology

Mansour M. Alqahtani^{1,*}, Maajid Mohi Ud Din Malik² and Ajai Kumar Shukla³

¹ Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

³ Department of Nuclear Medicine, Dr. Ram Manohar Lohia Institute of Medical Sciences, Gomti Nagar, Lucknow, India

Abstract: Theranostics, the integration of diagnostics and therapeutics, has revolutionised oncology and is now poised to transform other medical fields. This chapter explores the emerging applications of theranostics beyond cancer, focusing on three key areas: rheumatology, infectious diseases, and psychiatric disorders. In rheumatology, theranostic approaches offer promise for early diagnosis and targeted treatment of inflammatory joint diseases, with molecular imaging techniques such as folate receptor and fibroblast activation protein (FAP) imaging showing potential for both diagnostic and therapeutic applications. The chapter discusses novel targets, including type II collagen for osteoarthritis detection, and emerging therapeutic strategies like folate-targeted drug delivery and CD20-targeted radioimmunotherapy. In the realm of infectious diseases, theranostics presents innovative solutions for rapid pathogen identification and targeted antimicrobial therapy. The chapter examines advances in molecular imaging of infection, including the use of radiolabeled antibiotics and antimicrobial peptides. Theranostic applications such as nanoparticle-based systems and bacteriophage-mediated approaches for detecting and treating antibiotic-resistant infections are explored, highlighting their potential to address critical challenges in infectious disease management. The application of theranostics to psychiatric disorders represents a frontier in mental health research. The chapter discusses the use of molecular imaging to investigate neurotransmitter systems and neuroinflammation in conditions like depression and schizophrenia. Emerging theranostic concepts, such as using imaging to guide personalised antidepressant selection and targeted neuromodulation, are presented, along with the challenges and ethical considerations specific to psychiatric applications. The chapter concludes by comparing theranostic approaches across these fields, discussing common challenges, and exploring future directions. It emphasises the potential of theranostics to enable more precise diagnosis, personalised treatment strategies, and improved monitoring of

* Corresponding author Mansour M. Alqahtani: Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia; E-mail: mmalqahtane@nu.edu.sa

disease progression and treatment response across various medical specialities. The integration of theranostics with other emerging technologies, such as artificial intelligence and multi-omics data analysis, is highlighted as a promising avenue for advancing personalised medicine beyond oncology.

Keywords: Molecular imaging, Personalised medicine, Radiopharmaceuticals, Targeted therapy, Theranostics.

INTRODUCTION

Theranostics, a portmanteau of therapeutics and diagnostics, represents a paradigm shift in medicine, offering a personalised approach to patient care by combining diagnostic imaging and targeted therapy. While theranostics has gained significant traction in oncology, its potential extends far beyond cancer treatment. This chapter explores the emerging applications of theranostics in three key areas: rheumatology, infectious diseases, and psychiatric disorders.

The concept of theranostics is rooted in the idea of using the same molecular target for both imaging and therapy. This approach allows for the selection of patients most likely to benefit from a specific treatment, as well as monitoring treatment response and adjusting therapy accordingly. In nuclear medicine, theranostics typically involves the use of radiopharmaceuticals that can be employed for both diagnostic imaging (using gamma-emitting or positron-emitting isotopes) and therapy (using beta-emitting or alpha-emitting isotopes).

The expansion of theranostics beyond oncology is unified by several overarching principles that transcend medical specialities and create a coherent framework for understanding its transformative potential. Fundamentally, all theranostic applications share the common goal of achieving molecular-level precision in both diagnosis and treatment, whether targeting inflammatory macrophages in rheumatoid arthritis, bacterial pathogens in infectious diseases, or neurotransmitter systems in psychiatric disorders. This precision is enabled by the unique ability of theranostic agents to provide quantitative, real-time assessment of target expression or biological processes, followed by targeted delivery of therapeutic interventions to the same molecular pathways.

The convergence of theranostic principles across diverse medical fields reflects a fundamental shift from organ-based medicine to molecular-targeted approaches that recognise disease as a constellation of disrupted molecular processes rather than isolated anatomical abnormalities. In rheumatology, this manifests as targeting activated immune cells rather than treating joints; in infectious diseases, as targeting specific pathogens rather than empirically treating suspected

infections; and in psychiatry, as modulating specific neurotransmitter pathways rather than employing broad-spectrum psychopharmacological interventions.

This molecular convergence creates opportunities for cross-fertilisation of approaches between medical specialities, where successful targeting strategies developed for one field can be adapted and applied to others. For example, the folate receptor targeting strategies developed for rheumatology applications may prove valuable for targeting activated macrophages in neuroinflammation associated with psychiatric disorders. In contrast, antimicrobial peptide approaches from infectious disease applications could potentially address bacterial components of autoimmune disease pathogenesis. Understanding these unifying principles enables clinicians and researchers to appreciate theranostics as a comprehensive medical paradigm rather than a collection of isolated techniques.

As our understanding of disease mechanisms at the molecular level continues to grow, so does the potential for applying theranostic approaches to a broader range of medical conditions. In rheumatology, theranostics offers the promise of early diagnosis and targeted treatment of inflammatory joint diseases. For infectious diseases, theranostic agents could provide rapid identification of pathogens and delivery of antimicrobial therapy. In the realm of psychiatric disorders, theranostics may enable more precise diagnosis and personalised treatment strategies for conditions that have long challenged conventional diagnostic and therapeutic approaches.

This chapter will delve into these emerging applications, exploring the current state of research, potential clinical implications, and challenges that must be overcome to bring these innovative approaches into routine clinical practice. By examining theranostics beyond its traditional oncological applications, we aim to highlight the broad potential of this approach in shaping the future of personalised medicine across various medical specialities.

EMERGING APPLICATIONS IN RHEUMATOLOGY

Rheumatological disorders, characterised by inflammation of joints, muscles, and connective tissues, present significant diagnostic and therapeutic challenges. The application of theranostic principles in rheumatology offers the potential for earlier diagnosis, more precise treatment selection, and improved monitoring of disease progression and treatment response.

Molecular Targets in Rheumatology

Several molecular targets have shown promise for theranostic applications in rheumatology:

Nuclear Medicine in the Era of Precision Medicine

Rajesh S Kuber^{1,*}, Maajid Mohi Ud Din Malik² and Mansour M. Alqahtani³

¹ Department of Radio-Diagnosis, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University)- Sant Tukaram Nagar, Pune, India

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

³ Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia

Abstract: Nuclear medicine stands at the forefront of the precision medicine revolution, offering unique insights into molecular processes that complement and enhance other precision approaches. This chapter explores the integration of nuclear medicine with cutting-edge technologies and methodologies in the era of precision medicine, focusing on three key areas: integration with genomics and proteomics, radiomics and texture analysis, and personalised treatment planning and monitoring. The synergy between nuclear medicine and genomics/proteomics has opened new avenues for understanding disease biology and developing targeted therapies. By combining molecular imaging data with genomic and proteomic profiles, researchers and clinicians can gain a more comprehensive view of disease processes, enabling more accurate diagnosis, prognosis, and treatment selection. The chapter discusses examples of this integration in oncology, highlighting how it has improved patient stratification and treatment response prediction. Radiomics and texture analysis have expanded the information that can be extracted from nuclear medicine images, providing new biomarkers for various clinical applications. The chapter explores how these advanced image analysis techniques can reveal subtle patterns and features not apparent to the human eye, enhancing tumour characterisation, treatment response assessment, and prognostication. In the realm of personalised treatment planning and monitoring, nuclear medicine techniques enable truly individualised approaches. From initial target identification and characterisation to adaptive therapy strategies and long-term surveillance, molecular imaging plays a crucial role in guiding treatment decisions and assessing efficacy. The chapter discusses various applications, including theranostics, PET-guided radiotherapy, and novel approaches to monitoring immunotherapy response. Challenges and future directions are addressed, including the need for standardisation, the potential of artificial intelligence in image analysis, and the development of novel tracers and theranostic pairs. The integration of nuclear

* Corresponding author **Rajesh S Kuber**: Department of Radio-Diagnosis, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University)- Sant Tukaram Nagar, Pune, India; E-mail: rajesh.kuber@dpu.edu.in

medicine data with other biomarkers and its incorporation into clinical decision support systems are highlighted as key areas for future development. By providing a comprehensive overview of these advances, this chapter illustrates how nuclear medicine is driving innovations in precision medicine, offering non-invasive, quantitative assessments of molecular processes that bridge the gap between scientific discoveries and clinical application. As the field continues to evolve, nuclear medicine is poised to play an increasingly central role in translating the promise of precision medicine into improved patient outcomes across a broad spectrum of diseases.

Keywords: Precision medicine, molecular imaging, radiomics, theranostics, personalised treatment.

INTRODUCTION

The advent of precision medicine has ushered in a new era in healthcare, promising tailored treatments based on individual patient characteristics. Nuclear medicine, with its unique ability to provide functional and molecular information, is at the forefront of this revolution. This chapter explores the integration of nuclear medicine with cutting-edge technologies and approaches in precision medicine, focusing on three key areas: integration with genomics and proteomics, radiomics and texture analysis, and personalised treatment planning and monitoring.

Precision medicine aims to move beyond the “one-size-fits-all” approach to medical care, instead offering targeted prevention and treatment strategies based on an individual's genetic makeup, environment, and lifestyle. Nuclear medicine techniques, particularly molecular imaging with positron emission tomography (PET) and single-photon emission computed tomography (SPECT), provide crucial insights into the molecular basis of diseases, complementing the information obtained from genomics and proteomics.

The integration of nuclear medicine with these emerging fields is creating new opportunities for early disease detection, more accurate diagnosis, and personalised treatment strategies. This chapter will delve into the synergies between nuclear medicine and other precision medicine approaches, exploring how these combinations are reshaping our understanding of diseases and transforming patient care.

INTEGRATION WITH GENOMICS AND PROTEOMICS

The Promise of Multi-Omics Integration

The integration of nuclear medicine with genomics and proteomics represents a powerful approach to understanding disease at a molecular level. This multi-

omics integration allows for a more comprehensive view of biological processes, enabling more precise diagnosis and treatment strategies.

Genomics and Nuclear Medicine

Genomic information can guide the selection and interpretation of nuclear medicine studies. For instance, Kumar *et al.* (2019) demonstrated that combining ^{18}F -FDG PET/CT imaging with genomic profiling in non-small cell lung cancer (NSCLC) patients improved treatment response prediction [1]. They found that specific gene mutations correlated with patterns of FDG uptake, providing a more accurate prognosis than either method alone.

Conversely, nuclear medicine imaging can help validate and contextualise genomic findings. Yip *et al.* (2020) used ^{68}Ga -PSMA PET/CT to assess the clinical significance of novel genomic alterations in prostate cancer. They found that specific genetic variants were associated with increased PSMA expression and metastatic spread, demonstrating the value of combining imaging and genomic data [2].

Proteomics and Nuclear Medicine

Proteomic analysis can identify potential targets for nuclear medicine imaging and therapy. Chen *et al.* (2018) utilised mass spectrometry-based proteomics to identify overexpressed proteins in pancreatic cancer [3]. This led to the development of a novel PET tracer targeting one of these proteins, improving the detection of pancreatic tumours in preclinical models.

Nuclear medicine techniques can also contribute to proteomic research. Guo *et al.* (2021) used ^{89}Zr -immuno-PET to track the biodistribution of a therapeutic antibody *in vivo* [4]. By combining this imaging data with proteomic analysis of tissue samples, they were able to identify mechanisms of drug resistance and suggest potential combination therapies.

MASS SPECTROMETRY METHODOLOGIES AND CLINICAL TRANSLATION

The integration of nuclear medicine with proteomics relies heavily on sophisticated mass spectrometry techniques that enable comprehensive protein identification and quantification in biological samples. The most widely employed approach is liquid chromatography-tandem mass spectrometry (LC-MS/MS), which combines high-resolution protein separation with precise molecular identification through fragmentation patterns. In the context of nuclear medicine applications, targeted proteomics using selected reaction monitoring (SRM) or

Future Horizons in Nuclear Medicine

Mansour M. Alqahtani^{1,*} and Maajid Mohi Ud Din Malik²

¹ Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia

² Dr. D.Y. Patil School of Allied Health Sciences, Dr. D.Y. Patil Vidyapeeth, Pune (Deemed to be University), Sant Tukaram Nagar, Pune, India

Abstract: Nuclear medicine stands at the cusp of a transformative era, poised to leverage emerging technologies that promise to revolutionise diagnosis, treatment, and patient care. This chapter explores the exciting future horizons of nuclear medicine, examining emerging technologies, the potential impacts of quantum computing and nanotechnology, and the ethical considerations that will guide these advancements. Next-generation imaging systems, including total-body PET scanners and advanced SPECT technologies, are set to enhance sensitivity and reduce radiation exposure. Artificial intelligence and quantum computing offer the potential for improved image reconstruction, analysis, and personalised treatment planning. Nanotechnology presents opportunities for novel radiopharmaceuticals and theranostic agents with unprecedented precision. The chapter also addresses the ethical implications of these advancements, emphasising the importance of patient privacy, equitable access to technology, and responsible innovation. By providing a comprehensive overview of the future landscape of nuclear medicine, this chapter aims to prepare practitioners for the challenges and opportunities that lie ahead, ensuring that the field continues to evolve in ways that prioritise patient care and societal benefit.

Keywords: Artificial intelligence, Ethical considerations, Nanotechnology, Quantum computing, Theranostics, Total-body PET.

INTRODUCTION

Nuclear medicine stands at the cusp of a new era, poised to leverage emerging technologies that promise to revolutionise diagnosis, treatment, and patient care. As we look towards the future, it is clear that the field will be shaped by advancements not only in medical science but also in computing, materials science, and nanotechnology. This chapter explores the exciting horizons of nuclear medicine, examining emerging technologies, the potential impacts of

* Corresponding author Mansour M. Alqahtani: Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia; E-mail: mmalqahtane@nu.edu.sa

quantum computing and nanotechnology, and the ethical considerations that will guide these advancements.

The relentless pace of technological innovation has already transformed nuclear medicine in recent decades. From the development of hybrid imaging modalities to the rise of theranostics, the field has continually evolved to provide more precise, personalised, and effective patient care. However, the innovations on the horizon promise to take these capabilities to new heights, offering unprecedented insights into disease processes and novel therapeutic approaches.

As we delve into these future horizons, it is crucial to consider not only the technical possibilities but also their broader implications for healthcare systems, patient experiences, and societal values. The integration of advanced technologies into nuclear medicine raises critical ethical questions about data privacy, equitable access to healthcare, and the changing nature of the doctor-patient relationship.

This chapter aims to provide a comprehensive overview of the future landscape of nuclear medicine. We will explore emerging technologies that are set to redefine imaging and therapy, examine the transformative potential of quantum computing and nanotechnology, and consider the ethical dimensions of these advancements. By understanding these future horizons, we can better prepare for the challenges and opportunities that lie ahead, ensuring that nuclear medicine continues to evolve in ways that prioritise patient care and societal benefit.

EMERGING TECHNOLOGIES ON THE HORIZON

A diverse array of emerging technologies will shape the future of nuclear medicine, each offering unique capabilities and potential applications. This section explores some of the most promising technological advancements on the horizon.

Next-Generation Imaging Systems

Total-Body PET Scanners

Total-body PET scanners represent a significant leap forward in molecular imaging. These systems, with their extended axial field of view, allow for simultaneous imaging of the entire body, offering several advantages:

1. **Increased Sensitivity:** Total-body PET scanners can detect smaller lesions and lower tracer concentrations, potentially enabling earlier disease detection.
2. **Reduced Scan Times:** The increased sensitivity allows for shorter acquisition times, improving patient comfort and throughput.

3. Reduced Radiation Dose: Lower doses of radiopharmaceuticals can be used while maintaining image quality.

Cherry *et al.* (2018) demonstrated that total-body PET could achieve up to 40 times higher sensitivity compared to conventional PET systems, opening up new possibilities for dynamic whole-body imaging and ultra-low-dose studies [1].

COMPARATIVE PERFORMANCE ANALYSIS: NEXT-GENERATION VS. CURRENT TECHNOLOGIES

The transformative potential of next-generation imaging systems becomes most apparent when compared directly to current clinical standards, revealing quantifiable improvements that justify the substantial investments required for implementation. Total-body PET scanners represent perhaps the most dramatic advancement, offering capabilities that fundamentally exceed the physical limitations of conventional systems rather than providing incremental improvements.

TOTAL-BODY PET: QUANTITATIVE PERFORMANCE COMPARISONS

Current conventional PET/CT systems with 15-25 cm axial field of view require 15-20 minutes for whole-body imaging with standard ^{18}F -FDG doses of 370-555 MBq (10-15 mCi). In contrast, total-body PET systems with 194 cm axial coverage achieve equivalent image quality in 30-60 seconds using doses as low as 37-74 MBq (1-2 mCi), representing a 10-15 fold reduction in scanning time and a 5-10 fold reduction in radiation exposure. This performance improvement translates to practical clinical advantages, including the elimination of patient motion artefacts, the ability to image critically ill patients who cannot remain still for extended periods, and the potential for dynamic whole-body studies that were previously technically impossible.

The economic implications are equally significant, with total-body PET enabling patient throughput increases of 400-600% compared to conventional systems. While capital costs are 2-3 times higher (\$4-6 million versus \$1.5-2.5 million), the enhanced throughput and reduced radiopharmaceutical costs generate a positive return on investment within 18-24 months for centres performing more than 1,500 studies annually. Early adopter institutions report operational cost reductions of 25-35% per study through decreased radiopharmaceutical usage and improved scheduling efficiency.

SUBJECT INDEX

A

Absolute quantification 36, 73, 74, 102, 161, 224
 Acquisition protocols 190, 194, 273, 280, 292
 Adaptive 48, 97, 126, 253, 293, 355,
 geometries 48
 imaging protocols 126, 293
 radiotherapy 97, 253, 355,
 Advanced 4, 6, 16, 17, 35, 45, 83, 87, 190,
 193, 194, 229, 209, 334, 364, 367
 detector designs 87
 imaging technologies 4, 16, 190, 193, 334
 reconstruction algorithms 6, 17, 35, 45, 83,
 194, 229, 209
 SPECT technologies 364, 367
 Alzheimer's disease (AD) 7, 19, 90, 101, 125,
 151, 153, 156, 166, 170, 173, 176, 177,
 178, 183, 189, 278, 325
 Angiogenesis 29, 91, 226
 Annexin a5 214, 215
 Antimicrobial resistance 319, 322, 333
 Apoptosis 214
 Artificial intelligence (AI) 1, 6, 9, 15, 25, 30,
 42, 59, 68, 71, 73, 80, 83, 94, 97, 103,
 108, 109, 113, 116, 117, 119, 121, 127,
 138, 146, 180, 206, 209, 212, 227, 233,
 253, 259, 260, 265, 276, 278, 282,, 293,
 298, 309, 314, 329, 337, 359, 364, 368,
 377
 Atherosclerosis 162, 163, 212, 213, 214, 215,
 216, 217, 218, 219
 Axial field of view (AFOV) 5, 16, 42, 46, 54,
 76, 86, 102, 365, 366

B

Bacteriophage-based theranostics 320, 328
 Beta-emitting radionuclides 31, 32, 34
 Big data 9, 10, 11, 65, 332, 376
 Bismuth germanate (BGO) 44
 Blood-brain barrier 124, 280, 324

Brain 72, 79, 82, 132, 156, 160, 179, 183, 191,
 204, 207, 246, 271
 atrophy 179, 183
 tumours 72, 79, 82, 132, 156, 160, 191, 204,
 207, 246, 271
 Breast cancer 24, 77, 86, 90, 92, 132, 157,
 160, 241, 251, 275, 276, 345, 347

C

Cadmium zinc telluride (CZT) 5, 73, 84, 100,
 227, 290, 367
 Calibration 35, 37, 64, 84, 94, 145, 209, 267,
 268
 Cancer-associated fibroblasts 26, 133, 157
 Cardiac 5, 34, 78, 112, 161, 163, 164, 225,
 227, 270, 291, 302
 amyloidosis 34, 163, 164
 innervation imaging 161
 sarcoidosis 78, 225
 SPECT 5, 112, 227, 270, 291, 302
 Cardiovascular imaging 5, 78, 82, 91, 97, 101,
 102, 150, 163, 164, 229
 Carotid plaques 214, 215
 Cell proliferation 246, 274
 Cerebrospinal fluid (CSF) 177, 179, 180, 340
 Cerenkov luminescence imaging (CLI) 237,
 240, 254
 Chelator development 137
 Chemotherapy 32, 118, 145, 203, 232, 248,
 249, 251, 274
 Chronic traumatic encephalopathy 19, 175
 Click chemistry 137, 138
 Collimator design 74, 85, 86, 100, 367
 Convolutional neural networks (CNNs) 59,
 110, 115, 116, 119, 277, 279, 348
 Coronary artery disease (CAD) 6, 10, 72, 78,
 91, 112, 161, 164, 224, 228
 Cyclotron 2, 93, 158, 164, 173, 369, 370

D

Dementia 19, 79, 152, 173, 175, 178, 179, 188
Depth-of-interaction (DOI) detection 45
Diagnostic reference levels (DRLs) 196, 301, 303, 305
Digital pet 3, 5, 17, 44, 46, 47, 62, 75, 193, 291, 294, 308
Dose 12, 13, 15, 17, 18, 25, 37, 51, 58, 59, 60, 66, 75, 111, 115, 190, 191, 192, 194, 196, 203, 288, 289, 290, 293, 301, 303, 306, 307, 309
 optimisation 12, 15, 37, 194, 288, 289, 290, 293, 301, 303, 306, 307, 309
 reduction 13, 17, 18, 25, 51, 58, 59, 60, 66, 75, 111, 115, 190, 191, 192, 203
 tracking software 196
Dosimetry 6, 8, 13, 15, 18, 24, 33, 34, 36, 57, 89, 119, 120, 134, 137, 138, 141, 192, 249, 250, 252, 275, 288
Dynamic imaging 18, 54, 56, 89, 115, 199, 200, 277, 278, 368, 270

E

Epilepsy 72, 78, 79, 101, 191, 204, 205, 207, 278, 280
Explorer total-body PET/CT scanner 5, 16

F

Federated learning 60, 124, 127, 280, 284
Fibroblast activation protein inhibitors (FAPIs) 1, 26, 125, 157
Filtered back projection (FBP) 6, 45, 110, 269, 292
Fluorescence-guided surgery 239
Folate receptor β (FR- β) 316, 319
Frontotemporal dementia 19, 152, 175, 188

G

Gamma camera 2, 3, 237, 240, 251, 320
Genomics 63, 125, 285, 338, 339, 340, 341, 342, 343, 348, 358, 359, 368, 380
Gleason scores 345, 348
Glucose metabolism 6, 79, 183, 205, 219, 271, 325, 349

H

Handheld gamma probes 233, 235, 236, 240, 320
Head and neck cancer 77, 118, 159, 241, 242, 252, 255, 276, 347, 350
Heart failure management 212, 213, 222, 223, 227, 229
Hybrid imaging systems 4, 72, 234, 235
Hypoxia 6, 159, 246, 274, 349, 350

I

Image 9, 10, 17, 25, 35, 42, 43, 45, 53, 55, 59, 71, 74, 95, 108, 109, 110, 111, 112, 113, 119, 125, 126, 216, 227, 253, 273, 285, 292, 309, 335, 344, 368, 370, 373, 380
 interpretation 10, 108, 112, 113, 126, 253, 335
 reconstruction 9, 17, 35, 42, 43, 45, 53, 55, 59, 71, 74, 95, 108, 109, 110, 111, 125, 216, 227, 273, 285, 292, 309, 368, 370, 373, 380
 segmentation 10, 25, 119, 344
Immuno-PET 29, 90, 160, 339, 343
Immunotherapy 24, 29, 119, 137, 145, 203, 249, 253, 272, 347, 350, 356, 358, 372
Implantable cardioverter-defibrillator (ICD) therapy 225
Infectious diseases 313, 314, 319, 322, 328, 329, 330
Integrin targeting 24
Ischemic 219, 220, 222
 cardiomyopathy 219, 220
 heart disease 222
Iterative reconstruction 17, 45, 50, 74, 75, 110, 269, 292, 293, 370

K

Kinetics 43, 82, 125, 199, 200, 270, 278, 297, 299, 352

L

Lesion detection 10, 18, 25, 96, 112, 114, 124, 253, 256, 276
Liquid biopsies 343, 354
Lymphoma 8, 77, 201, 272, 276, 350, 353

M

Machine learning algorithms 59, 108, 109, 118, 120, 146, 206, 209, 228, 284, 233, 329, 343, 368, 370, 371
 Mammography 237
 Melanoma 118, 236, 240, 241, 244, 251, 351, 352
 Metastatic castration-resistant prostate cancer (mCRPC) 22, 28, 33, 136, 248, 252, 373
 Microfluidic radiochemistry 369, 370
 Mitochondrial function 212, 220
 Monte carlo simulations 6, 35, 298, 299, 371
 Multimodal imaging 3, 18, 42, 61, 62, 68, 119, 206, 318, 371, 372
 Myocardial perfusion imaging 4, 10, 78, 161, 222, 224, 291, 293, 367
 Myocardial viability assessment 212, 218, 221, 222

N

Nanotechnology 30, 34, 260, 364, 369, 371, 373, 377, 385
 Neuroblastoma 202, 203, 207, 246, 250, 275, 276
 Neuroendocrine tumours (NETs) 8, 23, 31, 79, 86, 129, 132, 138, 140, 247, 248, 341, 353
 Neuroinflammation imaging 20, 154, 155, 182, 185, 186
 Next-generation imaging systems 38, 364, 365, 366

O

Ordered subset expectation maximisation (OSEM) 6, 45, 110, 194, 269, 292

P

Pancreatic cancer 27, 339, 340, 343, 352
 Parkinson's disease progression 184
 Partial volume correction (PVC) 37, 84, 228, 257, 270
 Patient 9, 14, 22, 27, 90, 93, 129, 134, 139, 142, 160, 221, 246, 304, 325, 343, 349, 355, 357, 381, 382
 education 14, 304, 325, 381, 382

selection 9, 22, 27, 90, 93, 129, 134, 139, 142, 160, 221, 246, 343, 349, 355, 357
 Peptide receptor radionuclide therapy (PRRT) 23, 117, 138, 139, 246, 247, 252, 298,
 Photosensors 44, 45, 46, 51
 Proteomics 63, 125, 332, 337, 338, 339, 340, 343, 358, 359
 Psychiatric disorders 18, 20, 151, 154, 156, 313, 322, 324, 325, 328, 329

Q

Quantitative imaging 10, 15, 31, 71, 137, 167, 256, 265, 266, 269, 282
 Quantum computing 125, 364, 365, 370, 371, 372, 373, 377, 378, 382

R

Radiation safety 12, 14, 15, 144, 216, 288, 299, 300, 303-306, 308, 309, 331
 Radiochemistry 7, 26, 135, 137, 150, 167, 369, 371, 374, 375
 Radio-guided surgery 233, 234, 235, 250, 253, 255, 256, 259, 260, 361
 Radioguided occult lesion localisation (ROLL) 237, 238, 251
 Radiomics 10, 11, 57, 103, 108, 117, 118, 212, 253, 338, 344, 347, 348, 356, 368, 370, 380
 Real-time dosimetry 15, 299, 373
 Resolution recovery 6, 13, 35, 74, 95, 194, 270, 292
 Rheumatology 313, 314, 315, 317, 318, 328, 329, 331, 334

S

Sarcoidosis 78, 79, 225
 Scatter correction 6, 35, 55, 76, 87, 270
 Sentinel lymph node mapping 4, 86, 92, 101, 233, 234, 235, 237, 239, 240, 241, 242, 243, 250, 256
 Silicon photomultipliers (SiPMs) 5, 44, 49, 75, 81, 87, 101, 291
 Somatostatin receptors (SSTRs) 23, 26, 79, 132, 138, 143, 160
 Standardised uptake value (SUV) 59, 96, 114, 199, 202, 270, 274, 344

Synaptic density imaging 19, 20, 26, 29, 90,
153
Synthetic CT generation 293

T

Thyroid cancer 8, 79, 80, 93, 117, 120, 236,
246, 250, 296, 341
Time-of-flight (TOF) PET 5, 42, 43
Total-body PET 15, 16, 42, 53, 54, 55, 56, 58,
63, 76, 87, 88, 89, 102, 216, 227, 229,
260, 278, 329, 359, 364, 370, 376
Tumour characterisation 260, 279, 337, 344,
348, 368, 370

U

Ultra-low-dose imaging 368, 370, 382
Ultrasound 215, 237

V

Voxel-based dosimetry 137, 297, 298, 299

Y

Yttrium-90 8, 22, 31, 133, 134, 135



Maajid Mohi Ud Din Malik

Maajid Mohi Ud Din Malik, Ph.D. in Radiology and Imaging Technology, currently serves as an Assistant Professor at Dr. D.Y. Patil School of Allied Health Sciences in Pune, India. His career began as a Clinical Radiographer before transitioning to academia. Dr. Malik has authored over 20 books and published more than 38 research articles in international journals. He serves as Editor-in-Chief of two professional journals: the Journal of Advanced Research Perspectives and Radiology Hub. His research focuses on radiation safety and diagnostic imaging protocols, with particular emphasis on dose-length product estimation in CT scanning. He holds patents for innovative medical devices, including a Controlled Sanitizer Dispensing Device and a Portable Device for Measuring Nerve Damage Due to Diabetic Neuropathy. His achievements have earned him recognition such as "Kashmir's Most Influential Author."



Mansour M. Alqahtani

Dr. Mansour Alqahtani is a distinguished healthcare professional and academic leader who currently serves as the Head of Radiology at Najran University Hospital and holds the position of Assistant Professor at Najran University, Saudi Arabia. His journey in medical imaging began at King Khalid University, followed by valuable clinical experience at the prestigious Johns Hopkins Aramco Healthcare in Dhahran. Dr. Alqahtani's commitment to academic excellence is reflected in his international education, having earned his Master's degree from King's College London in 2018 and his PhD from the University of Sydney in 2023. His diverse experience spanning clinical practice, academic research, and healthcare leadership positions him uniquely at the intersection of practical radiological expertise and cutting-edge academic knowledge. As a leader in Saudi Arabia's medical education sector, he continues to contribute to the advancement of radiological sciences while nurturing the next generation of healthcare professionals.